,Gender,Unnamed: 1,Male,Female,Total,completion_month_year,year,year2,phase,Published paper,Published paper  YN,Published result in clicnicaltrials,others,R/O,official_title,source,source.1,intervention_names,Age eligible for study,Lowe limit of age < 18,Age upper limit,Age code upper limit,Study population,Country,Continent,Is there an extension study
0,"NCT01079351, NCT01128959",Lee 2015,95,108,203,,1900,3,,,n,,,O,"A Sequential, Open-Label Study of the Pharmacokinetics and Safety of Intravenous Carbamazepine Relative to Oral Carbamazepine in Adult Patients With Epilepsy",Lundbeck LLC,1,Intravenous Carbamazepine,18 years and older,n,nil,>/75,United States of America,1,North America,n
1,NCT00236730,Faught 1996,143,38,181,12/1/1990,1990,3,Phase 2,1,y,n,open label extension study data not recorded as not available,R,Double-Blind Parallel Comparison of Three Doses of Topiramate and Placebo in Refractory Partial Epilepsy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,United States of America,1,North America,Y
2,NCT00236691,,152,38,190,12/1/1990,1990,3,Phase 2,0,n,y,,R,"Double-Blind, Parallel Comparison of Three Doses of Topiramate and Placebo in Refractory Partial Epilepsy","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,United States of America,1,North America,N
3,NCT00236860,Ben-Menachem 1996,47,9,56,2/1/1992,1992,3,Phase 2,1,y,n,,R,Double-Blind Parallel Comparison of Topiramate 400 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,Sweden,3,Europe,N
3,NCT00236860,Ben-Menachem 1996,47,9,56,2/1/1992,1992,3,Phase 2,1,y,n,,R,Double-Blind Parallel Comparison of Topiramate 400 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,Norway,3,Europe,N
3,NCT00236860,Ben-Menachem 1996,47,9,56,2/1/1992,1992,3,Phase 2,1,y,n,,R,Double-Blind Parallel Comparison of Topiramate 400 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,Denmark,3,Europe,N
3,NCT00236860,Ben-Menachem 1996,47,9,56,2/1/1992,1992,3,Phase 2,1,y,n,,R,Double-Blind Parallel Comparison of Topiramate 400 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,Germany,3,Europe,N
4,NCT00236873,Sharief 1996,40,7,47,5/1/1993,1993,3,Phase 2,1,y,n,,R,Double-Blind Parallel Comparison of Topiramate 200 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,Sweden,3,Europe,N
4,NCT00236873,Sharief 1996,40,7,47,5/1/1993,1993,3,Phase 2,1,y,n,,R,Double-Blind Parallel Comparison of Topiramate 200 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,Spain,3,Europe,N
4,NCT00236873,Sharief 1996,40,7,47,5/1/1993,1993,3,Phase 2,1,y,n,,R,Double-Blind Parallel Comparison of Topiramate 200 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,United Kingdom of Great Britain and Northern Ireland,3,Europe,N
4,NCT00236873,Sharief 1996,40,7,47,5/1/1993,1993,3,Phase 2,1,y,n,,R,Double-Blind Parallel Comparison of Topiramate 200 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,France,3,Europe,N
5,NCT00236847,Tassinari 1996,47,13,60,7/1/1993,1993,3,Phase 2,1,y,n,,R,"Double-Blind, Parallel Comparison of Topiramate 300 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,United Kingdom of Great Britain and Northern Ireland,3,Europe,N
5,NCT00236847,Tassinari 1996,47,13,60,7/1/1993,1993,3,Phase 2,1,y,n,,R,"Double-Blind, Parallel Comparison of Topiramate 300 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,Italy,3,Europe,N
5,NCT00236847,Tassinari 1996,47,13,60,7/1/1993,1993,3,Phase 2,1,y,n,,R,"Double-Blind, Parallel Comparison of Topiramate 300 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,France,3,Europe,N
5,NCT00236847,Tassinari 1996,47,13,60,7/1/1993,1993,3,Phase 2,1,y,n,,R,"Double-Blind, Parallel Comparison of Topiramate 300 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,Norway,3,Europe,N
5,NCT00236847,Tassinari 1996,47,13,60,7/1/1993,1993,3,Phase 2,1,y,n,,R,"Double-Blind, Parallel Comparison of Topiramate 300 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,18-65,n,65,65-<75,Denmark,3,Europe,N
6,NCT00004297,Alldredge 2001,129,76,205,2/1/1999,1999,3,Phase 3,1,y,n,,R,Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus,Office of Rare Diseases (ORD),2,diazepam | lorazepam,18 years and older,n,nil,>/75,United States of America,1,North America,N
7,NCT00236704,Biton 1999,45,35,80,12/1/1999,1999,3,Phase 3,1,y,n,,R,Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,4 years and older,y,nil,>/75,United States of America,2,North America,N
7,NCT00236704,Biton 1999,45,35,80,12/1/1999,1999,3,Phase 3,1,y,n,,R,Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,4 years and older,y,nil,>/75,Costa Rica,2,North America,N
8,NCT02171195,2016,64,0,64,10/1/2000,2000,1,Phase 1,0,n,y,,R,"A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093 When Given to Healthy Male Adult Volunteers.",Bial - Portela C S.A.,1,BIA 2-093 | Placebo,18-35,n,35,19-54,United Kingdom of Great Britain and Northern Ireland,3,Europe,N
9,NCT00236886,ben menachem 2003,16,22,38,6/1/2000,2000,3,Phase 3,1,y,n,,O,"Prospective Pilot Study on Metabolism and Weight Changes in Subjects With Diagnosed Partial Onset Epilepsy, With or Without Secondarily Generalized Seizures and Treated With Topiramate.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,16 years and older,y,nil,>/75,Sweden,3,Europe,n
10,NCT00236743,Ritter 2000,45,38,83,10/1/2000,2000,3,Phase 3,1,y,n,,R,Topiramate (RWJ 17021-000) Clinical Trial In Children With Partial Onset Seizures,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,1_16,y,16,</18,United States of America,1,North America,Y
11,NCT00236717,Wheless 2004,65,54,119,11/1/2000,2000,3,Phase 3,1,y,n,,R,TOPAMAX (Topiramate) Monotherapy Comparison Trial to Standard Monotherapy in the Treatment of Newly Diagnosed Epilepsy (RWJ-17021-000); Phase IIIB,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,Topiramate; Carbamazepine; Valproate,6 years and older,y,nil,>/75,United States of America,1,North America,N
12,NCT02171234,2015,32,0,32,6/1/2001,2001,1,Phase 1,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093, in Young Healthy Male Volunteers.",Bial - Portela C S.A.,1,Placebo | BIA 2-093,18-45,n,45,19-54,United Kingdom of Great Britain and Northern Ireland,3,Europe,N
13,NCT00236756,Sachdeo 1999,53,45,98,2/1/2001,2001,3,Phase 3,1,y,n,,R,A Double-Blind Trial of Topiramate in Subjects With Lennox-Gastaut Syndrome.,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,12 months to 30 years,y,30,</18,United States of America,1,North America,N
14,NCT01678976,2015,6,6,12,4/1/2002,2002,3,Phase 1,0,n,y,,O,Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers,Bial - Portela C S.A.,1,BIA 2-093 | Oxcarbazepine,18–45,n,45,19-54,Portugal,3,Europe,n
15,NCT02170077,2017,57,87,144,11/1/2002,2002,3,Phase 2,0,n,y,,R,A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093 in Controlling Refractory Partial Seizures When Added to Ongoing Therapy,Bial - Portela C S.A.,1,BIA 2-093 | Placebo,18-65,n,65,65-<75,Portugal,3,Europe,N
16,NCT00230698,Gilliam 2003,130,122,252,8/1/2002,2002,3,Phase 3,1,y,n,,R,Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,3 years and older,y,nil,>/75,United States of America,2,"North America
Europe",Y
16,NCT00230698,Gilliam 2003,130,122,252,8/1/2002,2002,3,Phase 3,1,y,n,,R,Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,3 years and older,y,nil,>/75,Europe,2,"North America
Europe",Y
16,NCT00230698,Gilliam 2003,130,122,252,8/1/2002,2002,3,Phase 3,1,y,n,,R,Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,3 years and older,y,nil,>/75,Canada,2,"North America
Europe",Y
16,NCT00230698,Gilliam 2003,130,122,252,8/1/2002,2002,3,Phase 3,1,y,n,,R,Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,3 years and older,y,nil,>/75,Costa Rica,2,"North America
Europe",Y
19,NCT01679002,2015,6,6,12,12/1/2003,2003,1,Phase 1,0,n,y,,O,Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers,Bial - Portela C S.A.,1,BIA 2-093 | Oxcarbazepine,18-45,n,45,19-54,Portugal,3,Europe,n
20,NCT00615615,Glauser 2006,100,98,198,3/1/2003,2003,3,Phase 3,2,y,n,"2 publication, only original publication is recorded",R,"Evaluation of the Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures: A 28-Week Double-Blind, Placebo-Controlled Multi-center Trial",UCB Pharma,1,Levetiracetam,4_16,y,16,</18,United States of America,2,North America,Y
20,NCT00615615,Glauser 2006,100,98,198,3/1/2003,2003,3,Phase 3,2,y,n,"2 publication, only original publication is recorded",R,"Evaluation of the Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures: A 28-Week Double-Blind, Placebo-Controlled Multi-center Trial",UCB Pharma,1,Levetiracetam,4_16,y,16,</18,Canada,2,North America,Y
21,NCT00646711,Kernitsky 2005,10,6,16,12/1/2003,2003,3,Phase 2,1,y,y,,O,"A 14 Day Randomized, Open-Label, Cross-Over, Single Center, Outpatient Study of Depakote Delayed-Release or Depakote Sprinkle vs. Divalproex Sodium Extended-Release in Child and Adolescent Patients With Epilepsy",Abbott,1,Depakote Delayed-Release/Depakote Sprinkle | Depakote ER,6_17,y,17,</18,United States of America,1,North America,n
24,NCT00610454,Baulac 2007,12,13,25,8/1/2004,2004,3,Phase 2,1,y,n,,O,"Trial Evaluating the Safety and Tolerability of Levetiracetam Intravenous 15-minute Infusion, Administered in b.i.d. Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 65 Years Suffering From Partial Onset Seizures",UCB Pharma,1,Levetiracetam,16-65,y,65,65-<75,France,3,europe,n
24,NCT00610454,Baulac 2007,12,13,25,8/1/2004,2004,3,Phase 2,1,y,n,,O,"Trial Evaluating the Safety and Tolerability of Levetiracetam Intravenous 15-minute Infusion, Administered in b.i.d. Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 65 Years Suffering From Partial Onset Seizures",UCB Pharma,1,Levetiracetam,16-65,y,65,65-<75,Germany,3,europe,n
24,NCT00610454,Baulac 2007,12,13,25,8/1/2004,2004,3,Phase 2,1,y,n,,O,"Trial Evaluating the Safety and Tolerability of Levetiracetam Intravenous 15-minute Infusion, Administered in b.i.d. Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 65 Years Suffering From Partial Onset Seizures",UCB Pharma,1,Levetiracetam,16-65,y,65,65-<75,United Kingdom of Great Britain and Northern Ireland,3,europe,n
25,NCT00800215,Biton 2008,25,35,60,11/1/2004,2004,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Double-dummy, Randomized Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures With or Without Secondary Generalization",UCB Pharma,1,iv SPM 927 and oral placebo tablet | oral SPM 927 tablet and iv placebo | iv SPM 927 and oral placebo tablet | oral SPM 927 tablet and iv placebo,19-61,n,61,55-<65,United States of America,2,"North America 
Europe",Y
25,NCT00800215,Biton 2008,25,35,60,11/1/2004,2004,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Double-dummy, Randomized Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures With or Without Secondary Generalization",UCB Pharma,1,iv SPM 927 and oral placebo tablet | oral SPM 927 tablet and iv placebo | iv SPM 927 and oral placebo tablet | oral SPM 927 tablet and iv placebo,19-61,n,61,55-<65,Lithuania,2,"North America 
Europe",Y
26,NCT00643136,Haas 2007,12,5,17,6/1/2004,2004,3,Phase 3,1,y,n,,R,"Pregabalin BID Add-on Trial: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Single-Center Sleep EEG Study in Patients With Partial Seizures and Sleep Disturbance Part B: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Pregabalin Add-on Treatment",Pfizer,1,Pregabalin | Placebo,18 years and older,n,nil,>/75,Netherlands,3,Europe,N
27,NCT00160628,heo 2007,52,48,100,10/1/2004,2004,3,Phase 3,1,y,n,,O,"A Korea, Republic ofn Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Levetiracetam as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy for Bridging Purpose With a Similar Study on Caucasian Epileptic Subjects",UCB Pharma,1,Levetiracetam,18 years and older,n,nil,>/75,"Korea, Republic of",4,Asia,n
28,NCT00150774,Noachtar 2008,44,77,121,12/1/2004,2004,3,Phase 3,2,y,n,"2 publication, 1 with pooled analysis, in view of duplicate population, nly the original study data is extracted",R,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Treatment in Adolescents (__‰ 12 Years) and Adults (___ 65 Years) Suffering From Idiopathic Generalized Epilepsy With Myoclonic Seizures.",UCB Pharma,1,Levetiracetam,12_65,y,65,65-<75,Australia,2,"Oceania
Europe
North America",N
28,NCT00150774,Noachtar 2008,44,77,121,12/1/2004,2004,3,Phase 3,2,y,n,"2 publication, 1 with pooled analysis, in view of duplicate population, nly the original study data is extracted",R,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Treatment in Adolescents (__‰ 12 Years) and Adults (___ 65 Years) Suffering From Idiopathic Generalized Epilepsy With Myoclonic Seizures.",UCB Pharma,1,Levetiracetam,12_65,y,65,65-<75,New Zealand,2,"Oceania
Europe
North America",N
28,NCT00150774,Noachtar 2008,44,77,121,12/1/2004,2004,3,Phase 3,2,y,n,"2 publication, 1 with pooled analysis, in view of duplicate population, nly the original study data is extracted",R,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Treatment in Adolescents (__‰ 12 Years) and Adults (___ 65 Years) Suffering From Idiopathic Generalized Epilepsy With Myoclonic Seizures.",UCB Pharma,1,Levetiracetam,12_65,y,65,65-<75,Europe,2,"Oceania
Europe
North America",N
28,NCT00150774,Noachtar 2008,44,77,121,12/1/2004,2004,3,Phase 3,2,y,n,"2 publication, 1 with pooled analysis, in view of duplicate population, nly the original study data is extracted",R,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Treatment in Adolescents (__‰ 12 Years) and Adults (___ 65 Years) Suffering From Idiopathic Generalized Epilepsy With Myoclonic Seizures.",UCB Pharma,1,Levetiracetam,12_65,y,65,65-<75,North America,2,"Oceania
Europe
North America",N
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,France,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Belgium,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Australia,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Poland,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Germany,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,czechiaia,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,United Kingdom of Great Britain and Northern Ireland,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Argentina,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Finland,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Netherlands,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Bulgaria,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Mexico,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Switzerland,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Hungary,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Austria,3,"Europe
South America
North America",n
29,NCT00630968,steinhoff 2007,768,773,1541,2/1/2004,2004,3,Phase 4,2,y,n,"2 publication, 1 with interim analysis, full analysis is included",O,Trial Studying the Safety and Efficacy of KeppraÔÎ as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy,UCB Pharma,1,Levetiracetam (Keppra),16 years and older,y,nil,>/75,Ireland,3,"Europe
South America
North America",n
31,NCT00160550,Berkovic 2007,73,91,164,6/1/2005,2005,3,Phase 3,2,y,n,"2 publication, 1 with pooled analysis, in view of duplicate population, nly the original study data is extracted",R,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With 3000 mg/Day (Pediatric Target Dose of 60 mg/kg/Day) Oral Levetiracetam (LEV) (166, 250, and 500mg Tablets), in Adult and Pediatric Subjects (4-65 Years) Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic (PGTC) Seizures.",UCB Pharma,1,Levetiracetam,4–65,y,65,65-<75,Europe,2,"Europe
North America
Oceania",Y
31,NCT00160550,Berkovic 2007,73,91,164,6/1/2005,2005,3,Phase 3,2,y,n,"2 publication, 1 with pooled analysis, in view of duplicate population, nly the original study data is extracted",R,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With 3000 mg/Day (Pediatric Target Dose of 60 mg/kg/Day) Oral Levetiracetam (LEV) (166, 250, and 500mg Tablets), in Adult and Pediatric Subjects (4-65 Years) Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic (PGTC) Seizures.",UCB Pharma,1,Levetiracetam,4–65,y,65,65-<75,North America,2,"Europe
North America
Oceania",Y
31,NCT00160550,Berkovic 2007,73,91,164,6/1/2005,2005,3,Phase 3,2,y,n,"2 publication, 1 with pooled analysis, in view of duplicate population, nly the original study data is extracted",R,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With 3000 mg/Day (Pediatric Target Dose of 60 mg/kg/Day) Oral Levetiracetam (LEV) (166, 250, and 500mg Tablets), in Adult and Pediatric Subjects (4-65 Years) Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic (PGTC) Seizures.",UCB Pharma,1,Levetiracetam,4–65,y,65,65-<75,Mexico,2,"Europe
North America
Oceania",Y
31,NCT00160550,Berkovic 2007,73,91,164,6/1/2005,2005,3,Phase 3,2,y,n,"2 publication, 1 with pooled analysis, in view of duplicate population, nly the original study data is extracted",R,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With 3000 mg/Day (Pediatric Target Dose of 60 mg/kg/Day) Oral Levetiracetam (LEV) (166, 250, and 500mg Tablets), in Adult and Pediatric Subjects (4-65 Years) Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic (PGTC) Seizures.",UCB Pharma,1,Levetiracetam,4–65,y,65,65-<75,Australia,2,"Europe
North America
Oceania",Y
31,NCT00160550,Berkovic 2007,73,91,164,6/1/2005,2005,3,Phase 3,2,y,n,"2 publication, 1 with pooled analysis, in view of duplicate population, nly the original study data is extracted",R,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With 3000 mg/Day (Pediatric Target Dose of 60 mg/kg/Day) Oral Levetiracetam (LEV) (166, 250, and 500mg Tablets), in Adult and Pediatric Subjects (4-65 Years) Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic (PGTC) Seizures.",UCB Pharma,1,Levetiracetam,4–65,y,65,65-<75,New Zealand,2,"Europe
North America
Oceania",Y
32,NCT00043901,Biton 2005,62,55,117,3/1/2005,2005,3,Phase 4,1,y,n,,R,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects Wtih Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine,2 years and older,y,nil,>/75,United States of America,2,"North America
South America",Y
32,NCT00043901,Biton 2005,62,55,117,3/1/2005,2005,3,Phase 4,1,y,n,,R,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects Wtih Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine,2 years and older,y,nil,>/75,Argentina,2,"North America
South America",Y
32,NCT00043901,Biton 2005,62,55,117,3/1/2005,2005,3,Phase 4,1,y,n,,R,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects Wtih Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine,2 years and older,y,nil,>/75,Chile,2,"North America
South America",Y
32,NCT00043901,Biton 2005,62,55,117,3/1/2005,2005,3,Phase 4,1,y,n,,R,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects Wtih Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine,2 years and older,y,nil,>/75,Peru,2,"North America
South America",Y
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,Belgium ,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,czechiaia,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,Finland,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,France,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,Germany,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,Hungary,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,Italy,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,Poland,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,South Africa,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,Spain,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,Sweden,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,Netherlands,3,"Europe
Africa
",N
33,NCT00150787,Brodie 2007,317,259,576,11/1/2005,2005,3,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (__‰ 16 Years) Coming From the N01061 Trial.",UCB Pharma,1,LEVETIRACETAM,16 years and older,y,nil,>/75,United Kingdom of Great Britain and Northern Ireland,3,"Europe
Africa
",N
34,NCT00221988,Schoenberg 2017,5,15,20,9/1/2005,2005,3,,1,y,n,,R,"A Randomized, Double-Blind, Cross-Over Study of the Cognitive and Mood Effects of KEPPRA (Levetiracetam) Tablets in Healthy Older Adults.",University Hospitals Cleveland Medical Center,2,Levetiracetam (Keppra),65 -80,n,80,>/75,United States of America,1,North America,N
35,NCT00210574,2011,5,7,12,10/1/2006,2006,3,Phase 2,0,n,y,,O,A Pilot Study of Topiramate in Childhood Absence Epilepsy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate,4_9,y,9,</18,United States of America,1,North America,n
36,NCT00287053,2016,24,33,57,10/1/2006,2006,3,Phase 4,1,y,y,,R,Phase IV Study of the Effects of Divalproex Sodium on Food Intake and Energy Expenditure.,Pennington Biomedical Research Center,2,divalproex sodium,18-54,n,54,19-54,United States of America,1,North America,N
37,NCT00144872,2017,20,34,54,4/22/2006,2006,3,Phase 1,0,n,y,,O,Evaluation of Lamotrigine in Subjects With Absence Seizures,GlaxoSmithKline,1,Lamotrigine,up to 12 years,y,12,</18,United States of America,1,North America,n
38,NCT02170064,2017,12,17,29,4/1/2006,2006,3,Phase 2,0,n,y,,O,"Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 in Children and Adolescents With Refractory Partial Epilepsy",Bial - Portela C S.A.,1,BIA 2-093 (Eslicarbazepine acetate),2_17,y,17,</18,Romania,3,Europe,n
39,NCT00175825,2018,110,98,208,6/29/2006,2006,3,Phase 2,1,y,y,*Studies with pooled data,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam,16-65,y,65,65-<75,United States of America,2,"North America
South America
Asia
",N
39,NCT00175825,2018,110,98,208,6/29/2006,2006,3,Phase 2,1,y,y,*Studies with pooled data,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam,16-65,y,65,65-<75,Brazil,2,"North America
South America
Asia
",N
39,NCT00175825,2018,110,98,208,6/29/2006,2006,3,Phase 2,1,y,y,*Studies with pooled data,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam,16-65,y,65,65-<75,India,2,"North America
South America
Asia
",N
39,NCT00175825,2018,110,98,208,6/29/2006,2006,3,Phase 2,1,y,y,*Studies with pooled data,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam,16-65,y,65,65-<75,Mexico,2,"North America
South America
Asia
",N
39,NCT00175825,2018,110,98,208,6/29/2006,2006,3,Phase 2,1,y,y,*Studies with pooled data,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam,16-65,y,65,65-<75,,2,"North America
South America
Asia
",N
40,NCT00136019,Chung 2010,200,205,405,8/1/2006,2006,3,Phase 3,4,y,n,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization",UCB Pharma,1,SPM 927,16-70,y,70,65-<75,United States of America,1,North America,Y
41,NCT00162981,Conry 2009,42,26,68,10/1/2006,2006,3,Phase 2,1,y,n,,R,Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome,Lundbeck LLC,1,Clobazam Low Dose | Clobazam High Dose,2_30,y,30,19-54,United States of America,1,North America,Y
42,NCT00220415,Halasz 2009,250,235,485,1/1/2006,2006,3,Phase 3,4,y,n,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization",UCB Pharma,1,SPM 927,16-70,y,70,65-<75,Germany,3,Europe,Y
43,NCT00160654,Kwan 2010,114,137,251,5/1/2006,2006,3,Phase 4,1,y,n,,O,"A Phase IV, Open-label, Multi-center, Community-based Trial Studying the Safety and Efficacy of Keppra_Ê¢ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.",UCB Pharma,1,Levetiracetam,18 years and older,n,nil,>/75,Hong Kong,4,Asia,n
43,NCT00160654,Kwan 2010,114,137,251,5/1/2006,2006,3,Phase 4,1,y,n,,O,"A Phase IV, Open-label, Multi-center, Community-based Trial Studying the Safety and Efficacy of Keppra_Ê¢ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.",UCB Pharma,1,Levetiracetam,18 years and older,n,nil,>/75,Malaysia,4,Asia,n
43,NCT00160654,Kwan 2010,114,137,251,5/1/2006,2006,3,Phase 4,1,y,n,,O,"A Phase IV, Open-label, Multi-center, Community-based Trial Studying the Safety and Efficacy of Keppra_Ê¢ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.",UCB Pharma,1,Levetiracetam,18 years and older,n,nil,>/75,Philippines,4,Asia,n
43,NCT00160654,Kwan 2010,114,137,251,5/1/2006,2006,3,Phase 4,1,y,n,,O,"A Phase IV, Open-label, Multi-center, Community-based Trial Studying the Safety and Efficacy of Keppra_Ê¢ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.",UCB Pharma,1,Levetiracetam,18 years and older,n,nil,>/75,Singapore,4,Asia,n
43,NCT00160654,Kwan 2010,114,137,251,5/1/2006,2006,3,Phase 4,1,y,n,,O,"A Phase IV, Open-label, Multi-center, Community-based Trial Studying the Safety and Efficacy of Keppra_Ê¢ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.",UCB Pharma,1,Levetiracetam,18 years and older,n,nil,>/75,"Taiwan, Province of China",4,Asia,n
43,NCT00160654,Kwan 2010,114,137,251,5/1/2006,2006,3,Phase 4,1,y,n,,O,"A Phase IV, Open-label, Multi-center, Community-based Trial Studying the Safety and Efficacy of Keppra_Ê¢ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.",UCB Pharma,1,Levetiracetam,18 years and older,n,nil,>/75,Thailand,4,Asia,n
44,NCT00175929,Paesschen 2013,21,31,52,3/1/2006,2006,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam,16-65,y,65,65-<75,Belgium,3,Europe,Y
44,NCT00175929,Paesschen 2013,21,31,52,3/1/2006,2006,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam,16-65,y,65,65-<75,czechiaia,3,Europe,Y
44,NCT00175929,Paesschen 2013,21,31,52,3/1/2006,2006,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam,16-65,y,65,65-<75,Finland,3,Europe,Y
44,NCT00175929,Paesschen 2013,21,31,52,3/1/2006,2006,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam,16-65,y,65,65-<75,France,3,Europe,Y
44,NCT00175929,Paesschen 2013,21,31,52,3/1/2006,2006,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam,16-65,y,65,65-<75,Germany,3,Europe,Y
44,NCT00175929,Paesschen 2013,21,31,52,3/1/2006,2006,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam,16-65,y,65,65-<75,Netherlands,3,Europe,Y
44,NCT00175929,Paesschen 2013,21,31,52,3/1/2006,2006,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam,16-65,y,65,65-<75,Poland,3,Europe,Y
44,NCT00175929,Paesschen 2013,21,31,52,3/1/2006,2006,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam,16-65,y,65,65-<75,Spain,3,Europe,Y
44,NCT00175929,Paesschen 2013,21,31,52,3/1/2006,2006,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam,16-65,y,65,65-<75,United Kingdom of Great Britain and Northern Ireland,3,Europe,Y
44,NCT00175929,Paesschen 2013,21,31,52,3/1/2006,2006,3,Phase 2,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam,16-65,y,65,65-<75,,3,Europe,Y
45,NCT00264615,Tompson 2008,19,25,44,6/1/2006,2006,3,Phase 3,1,y,n,,O,"An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa",GlaxoSmithKline,1,lamotrigine extended-release,13 years and older,y,nil,>/75,United States of America,1,North America,n
46,NCT00275912,2008,31,29,60,9/28/2007,2007,1,Phase 4,0,n,y,,O,"A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures",Novartis,1,Oxcarbazepine,6 months to 17 years,y,17,</18,Russian Federation,3,Europe,n
47,NCT00939692,2013,14,12,26,4/1/2007,2007,1,Phase 1,0,n,y,,O,"Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Topiramate (2 x 25 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (TopamaxÔÎ, Ortho-McNeil Neurologics, Inc.)in Fasted, Healthy, Adult Subjects",Torrent Pharmaceuticals Limited,1,Topiramate,18-55,n,55,55-<65,United States of America,1,North America,n
48,NCT00957684,2014,48,54,102,2/1/2007,2007,1,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial.",Bial - Portela C S.A.,1,eslicarbazepine acetate | placebo,18 years and older,n,nil,>/75,Portugal,3,Europe,N
49,NCT00288639,2018,49,49,98,12/1/2007,2007,1,Phase 4,0,n,y,,O,"Lyrica (Pregabalin) Administered As An Add-On Therapy For Partial Seizures (LEADER) An Open-Label, Multicenter Add-On Therapy Trial",Pfizer,1,Pregabalin,18 years and older,n,nil,>/75,Greece,3,Europe,n
50,NCT00280696,Inoue 2015,171,180,351,11/1/2007,2007,1,Phase 3,0,n,n,,R,"A Double-blind, Randomized, Placebo-controlled 5 Parallel Groups, Confirmatory Trial on the Efficacy and Safety of Levetiracetam Used as add-on Therapy at Doses of 0.5 to 3 g/Day in Patients From 16 to 65 Years With Epilepsy With Partial Onset Seizures Under Treatment With 1 to 3 Anti-epileptic Drug(s)",UCB Pharma,1,Levetiracetam 250 mg | Levetiracetam 500 mg | Placebo,16-65,y,65,65-<75,Japan,4,Asia,Y
51,NCT00144690,Krauss 2011,67,86,153,2/1/2007,2007,1,Phase 2,1,y,n,,R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | Placebo,18-70,n,70,65-<75,United States of America,1,North America,N
52,NCT00105040,Levisohn 2009,56,42,98,3/1/2007,2007,1,Phase 2,2,y,n,"2 publication , with same population, only ITT data collect",R,"A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20 - 60 mg/kg/Day, Divided in Twice Daily Dosing, as Adjunctive Treatment in Children 4 - 16 Years Old, Inclusive, With Refractory Partial Onset Seizures",UCB Pharma,1,Levetiracetam | Placebo (PB),4_16,y,16,</18,United States of America,2,"North America
Africa",Y
52,NCT00105040,Levisohn 2009,56,42,98,3/1/2007,2007,1,Phase 2,2,y,n,"2 publication , with same population, only ITT data collect",R,"A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20 - 60 mg/kg/Day, Divided in Twice Daily Dosing, as Adjunctive Treatment in Children 4 - 16 Years Old, Inclusive, With Refractory Partial Onset Seizures",UCB Pharma,1,Levetiracetam | Placebo (PB),4_16,y,16,</18,Canada,2,"North America
Africa",Y
52,NCT00105040,Levisohn 2009,56,42,98,3/1/2007,2007,1,Phase 2,2,y,n,"2 publication , with same population, only ITT data collect",R,"A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20 - 60 mg/kg/Day, Divided in Twice Daily Dosing, as Adjunctive Treatment in Children 4 - 16 Years Old, Inclusive, With Refractory Partial Onset Seizures",UCB Pharma,1,Levetiracetam | Placebo (PB),4_16,y,16,</18,South Africa,2,"North America
Africa",Y
53,NCT00113165,Naritoku 2007,117,119,236,7/1/2007,2007,3,Phase 3,1,y,0,,R,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures",GlaxoSmithKline,1,LAMICTAL extended-release,13 years and older,y,nil,>/75,United States of America,2,"North America
South America
Europe
Asia",Y
53,NCT00113165,Naritoku 2007,117,119,236,7/1/2007,2007,3,Phase 3,1,y,0,,R,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures",GlaxoSmithKline,1,LAMICTAL extended-release,13 years and older,y,nil,>/75,Argentina,2,"North America
South America
Europe
Asia",Y
53,NCT00113165,Naritoku 2007,117,119,236,7/1/2007,2007,3,Phase 3,1,y,0,,R,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures",GlaxoSmithKline,1,LAMICTAL extended-release,13 years and older,y,nil,>/75,Brazil,2,"North America
South America
Europe
Asia",Y
53,NCT00113165,Naritoku 2007,117,119,236,7/1/2007,2007,3,Phase 3,1,y,0,,R,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures",GlaxoSmithKline,1,LAMICTAL extended-release,13 years and older,y,nil,>/75,Chile,2,"North America
South America
Europe
Asia",Y
53,NCT00113165,Naritoku 2007,117,119,236,7/1/2007,2007,3,Phase 3,1,y,0,,R,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures",GlaxoSmithKline,1,LAMICTAL extended-release,13 years and older,y,nil,>/75,Germany,2,"North America
South America
Europe
Asia",Y
53,NCT00113165,Naritoku 2007,117,119,236,7/1/2007,2007,3,Phase 3,1,y,0,,R,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures",GlaxoSmithKline,1,LAMICTAL extended-release,13 years and older,y,nil,>/75,India,2,"North America
South America
Europe
Asia",Y
53,NCT00113165,Naritoku 2007,117,119,236,7/1/2007,2007,3,Phase 3,1,y,0,,R,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures",GlaxoSmithKline,1,LAMICTAL extended-release,13 years and older,y,nil,>/75,"Korea, Republic of",2,"North America
South America
Europe
Asia",Y
53,NCT00113165,Naritoku 2007,117,119,236,7/1/2007,2007,3,Phase 3,1,y,0,,R,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures",GlaxoSmithKline,1,LAMICTAL extended-release,13 years and older,y,nil,>/75,Puerto Rico,2,"North America
South America
Europe
Asia",Y
53,NCT00113165,Naritoku 2007,117,119,236,7/1/2007,2007,3,Phase 3,1,y,0,,R,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures",GlaxoSmithKline,1,LAMICTAL extended-release,13 years and older,y,nil,>/75,Russian Federation,2,"North America
South America
Europe
Asia",Y
53,NCT00113165,Naritoku 2007,117,119,236,7/1/2007,2007,3,Phase 3,1,y,0,,R,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures",GlaxoSmithKline,1,LAMICTAL extended-release,13 years and older,y,nil,>/75,Ukraine,2,"North America
South America
Europe
Asia",Y
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,United States of America,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Argentina,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Australia,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Belgium,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Canada,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Chile,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Finland,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,France,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Hungary,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,India,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Israel,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,"Korea, Republic of",2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Mexico,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Netherlands,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,New Zealand,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Norway,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Poland,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Russian Federation,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,South Africa,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Spain,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,"Taiwan, Province of China",2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Thailand,2,"North America
South America
Oceania
Europe
Africa
Asia",N
54,NCT00113815,Novotny 2010,78,71,149,11/1/2007,2007,1,Phase 3,3,y,n,"3 publications, 2 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,topiramate | topiramate | topiramate | placebo,1 month to 24 months,y,2,</18,Ukraine,2,"North America
South America
Oceania
Europe
Africa
Asia",N
55,NCT00368069,Peltola 2009,99,59,158,5/1/2007,2007,3,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of KeppraÔÎ Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.",UCB Pharma,1,KeppraÔÎ extended release formulation - XR | Placebo,12–70,y,70,65-<75,Finland,3,"Europe
Asia
North America
Africa",N
55,NCT00368069,Peltola 2009,99,59,158,5/1/2007,2007,3,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of KeppraÔÎ Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.",UCB Pharma,1,KeppraÔÎ extended release formulation - XR | Placebo,12–70,y,70,65-<75,India,3,"Europe
Asia
North America
Africa",N
55,NCT00368069,Peltola 2009,99,59,158,5/1/2007,2007,3,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of KeppraÔÎ Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.",UCB Pharma,1,KeppraÔÎ extended release formulation - XR | Placebo,12–70,y,70,65-<75,Mexico,3,"Europe
Asia
North America
Africa",N
55,NCT00368069,Peltola 2009,99,59,158,5/1/2007,2007,3,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of KeppraÔÎ Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.",UCB Pharma,1,KeppraÔÎ extended release formulation - XR | Placebo,12–70,y,70,65-<75,Russian Federation,3,"Europe
Asia
North America
Africa",N
55,NCT00368069,Peltola 2009,99,59,158,5/1/2007,2007,3,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of KeppraÔÎ Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.",UCB Pharma,1,KeppraÔÎ extended release formulation - XR | Placebo,12–70,y,70,65-<75,South Africa,3,"Europe
Asia
North America
Africa",N
55,NCT00368069,Peltola 2009,99,59,158,5/1/2007,2007,3,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of KeppraÔÎ Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.",UCB Pharma,1,KeppraÔÎ extended release formulation - XR | Placebo,12–70,y,70,65-<75,Ukraine,3,"Europe
Asia
North America
Africa",N
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,United States of America,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,Argentina,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,Belgium,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,Brazil,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,Canada,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,czechia,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,France,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,Germany,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,Hungary,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,Italy,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,Mexico,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,Poland,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,Romania,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,Russian Federation,2,"North America
Europe
South America",Y
56,NCT00175890,Pin˜a-Garza 2005,57,59,116,1/1/2007,2007,1,Phase 3,2,y,n,"2 publication, 1 with OL , original study recorded",R,"A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009",UCB Pharma,1,Levetiracetam | Placebo,1 month - 4 years,y,4,</18,United Kingdom of Great Britain and Northern Ireland,2,"North America
Europe
South America",Y
57,NCT00233012,Puri 2010,27,23,50,10/1/2007,2007,1,Phase 1,2,y,n,"2 publication, both with pooled studies, only publication with result unique to NCT is included",O,"A Randomized, Open-label (OL), Multicenter Study With OL Extension of the Pharmacokinetics and Safety of Topiramate Administered as Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy in Infants (Aged 1-24 Months, Inclusive) With Refractory Partial-onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,Topiramate,1-24 months,y,2,</18,United States of America,2,"North America
Asia
Oceania
Europe",n
57,NCT00233012,Puri 2010,27,23,50,10/1/2007,2007,1,Phase 1,2,y,n,"2 publication, both with pooled studies, only publication with result unique to NCT is included",O,"A Randomized, Open-label (OL), Multicenter Study With OL Extension of the Pharmacokinetics and Safety of Topiramate Administered as Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy in Infants (Aged 1-24 Months, Inclusive) With Refractory Partial-onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,Topiramate,1-24 months,y,2,</18,Asia,2,"North America
Asia
Oceania
Europe",n
57,NCT00233012,Puri 2010,27,23,50,10/1/2007,2007,1,Phase 1,2,y,n,"2 publication, both with pooled studies, only publication with result unique to NCT is included",O,"A Randomized, Open-label (OL), Multicenter Study With OL Extension of the Pharmacokinetics and Safety of Topiramate Administered as Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy in Infants (Aged 1-24 Months, Inclusive) With Refractory Partial-onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,Topiramate,1-24 months,y,2,</18,Australia,2,"North America
Asia
Oceania
Europe",n
57,NCT00233012,Puri 2010,27,23,50,10/1/2007,2007,1,Phase 1,2,y,n,"2 publication, both with pooled studies, only publication with result unique to NCT is included",O,"A Randomized, Open-label (OL), Multicenter Study With OL Extension of the Pharmacokinetics and Safety of Topiramate Administered as Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy in Infants (Aged 1-24 Months, Inclusive) With Refractory Partial-onset Seizures","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,Topiramate,1-24 months,y,2,</18,Europe,2,"North America
Asia
Oceania
Europe",n
58,NCT00210782,Ramsay 2010,125,134,259,8/1/2007,2007,1,Phase 3,1,y,n,,R,"A Double-blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects With Seizures Indicative of New Onset Epilepsy","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",1,"topiramate, phenytoin",12_65,y,65,65-<75,United States of America,1,North America,Y
59,NCT00425282,sperling 2010,282,279,561,10/1/2007,2007,3,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.","SK Life Science, Inc.",1,RWJ-333369,16 years and older,y,nil,>/75,United States of America,2,"North America
South America
Asia
Europe",Y
59,NCT00425282,sperling 2010,282,279,561,10/1/2007,2007,3,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.","SK Life Science, Inc.",1,RWJ-333369,16 years and older,y,nil,>/75,South America,2,"North America
South America
Asia
Europe",Y
59,NCT00425282,sperling 2010,282,279,561,10/1/2007,2007,3,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.","SK Life Science, Inc.",1,RWJ-333369,16 years and older,y,nil,>/75,Europe,2,"North America
South America
Asia
Europe",Y
59,NCT00425282,sperling 2010,282,279,561,10/1/2007,2007,3,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.","SK Life Science, Inc.",1,RWJ-333369,16 years and older,y,nil,>/75,Asia,2,"North America
South America
Asia
Europe",Y
60,NCT00433667,Sperling 2010,267,288,555,10/1/2007,2007,1,Phase 3,1,y,y,"1 publication reporting 2 studies seperately, only demographic for study 2 corresponding to unique NCT reported",R,Epilepsy Phase III Trial,"SK Life Science, Inc.",1,RWJ-333369,16 years and older,y,nil,>/75,United States of America,2,"North America
South America
Europe
Asia",Y
60,NCT00433667,Sperling 2010,267,288,555,10/1/2007,2007,1,Phase 3,1,y,y,"1 publication reporting 2 studies seperately, only demographic for study 2 corresponding to unique NCT reported",R,Epilepsy Phase III Trial,"SK Life Science, Inc.",1,RWJ-333369,16 years and older,y,nil,>/75,South America,2,"North America
South America
Europe
Asia",Y
60,NCT00433667,Sperling 2010,267,288,555,10/1/2007,2007,1,Phase 3,1,y,y,"1 publication reporting 2 studies seperately, only demographic for study 2 corresponding to unique NCT reported",R,Epilepsy Phase III Trial,"SK Life Science, Inc.",1,RWJ-333369,16 years and older,y,nil,>/75,Europe,2,"North America
South America
Europe
Asia",Y
60,NCT00433667,Sperling 2010,267,288,555,10/1/2007,2007,1,Phase 3,1,y,y,"1 publication reporting 2 studies seperately, only demographic for study 2 corresponding to unique NCT reported",R,Epilepsy Phase III Trial,"SK Life Science, Inc.",1,RWJ-333369,16 years and older,y,nil,>/75,Asia,2,"North America
South America
Europe
Asia",Y
60,NCT00433667,Sperling 2010,267,288,555,10/1/2007,2007,1,Phase 3,1,y,y,"1 publication reporting 2 studies seperately, only demographic for study 2 corresponding to unique NCT reported",R,Epilepsy Phase III Trial,"SK Life Science, Inc.",1,RWJ-333369,16 years and older,y,nil,>/75,,2,"North America
South America
Europe
Asia",Y
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Australia,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Austria,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Belgium,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Bulgaria,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,czechiaia,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Denmark,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Finland,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,France,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Germany,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Greece,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Hungary,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Ireland,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Italy,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Netherlands,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Norway,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Poland,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Romania,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Russian Federation,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Slovakia,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Spain,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Sweden,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Switzerland,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,Turkey,3,"Oceania
Europe",n
61,NCT00175903,trinka 2012,942,746,1688,10/1/2007,2007,3,Phase 3,2,y,n,"2 publication, 1 with post hoc analysis, one is included",O,"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.",UCB Pharma,1,Levetiracetam | Carbamazepine Controlled Release (CBZ-CR) | Valproate Extended Release,16 years and older,y,nil,>/75,United Kingdom of Great Britain and Northern Ireland,3,"Oceania
Europe",n
62,NCT00510783,2013,49,109,158,12/1/2008,2008,1,Phase 4,0,n,y,,O,IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures,Emory University,2,Keppra | Fosphenytoin | Dilantin,18 years and older,n,nil,>/75,United States of America,1,North America,n
63,NCT00327717,2014,120,97,217,5/1/2008,2008,1,Phase 3,0,n,y,,R,"A Multicenter, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures",Eisai Inc.,1,Zonisamide | Placebo,16-70,y,70,65-<75,China,4,Asia,N
64,NCT00416195,2014,23,25,48,3/1/2008,2008,1,Phase 2,0,n,y,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures",Eisai Inc.,1,E2007 | Placebo,18-70,n,70,65-<75,Latvia,3,Europe,N
65,NCT00898560,2014,0,20,20,11/1/2008,2008,1,Phase 1,0,n,y,,O,Effect of Repeated Administration of Eslicarbazepine Acetate (BIA 2-093) 800mg Once-daily on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Female Subjects,Bial - Portela C S.A.,1,eslicarbazepine acetate and MicroginonÔÎ | MicroginonÔÎ,18-40,n,40,19-54,Portugal,3,Europe,n
66,NCT00957047,2014,194,201,395,1/1/2008,2008,1,Phase 3,0,n,y,,R,"Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial",Bial - Portela C S.A.,1,eslicarbazepine acetate | placebo | ESL - Part II,18 years and older,n,nil,>/75,Portugal,3,Europe,Y
67,NCT00957372,2014,113,140,253,6/1/2008,2008,1,Phase 3,0,n,y,,R,"Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Clinical Trial",Bial - Portela C S.A.,1,eslicarbazepine acetate | placebo (Part I) | ESL - Open-label Extension (Part II),18 years and older,n,nil,>/75,Portugal,3,Europe,Y
68,NCT00232596,2016,140,165,305,1/1/2008,2008,1,Phase 3,1,y,y,"1 publication reporting pooled analysis, result from clic gov are recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Placebo,18-75,n,75,>/75,United States of America,2,"North America
South America
",N
68,NCT00232596,2016,140,165,305,1/1/2008,2008,1,Phase 3,1,y,y,"1 publication reporting pooled analysis, result from clic gov are recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Placebo,18-75,n,75,>/75,Argentina,2,"North America
South America
",N
68,NCT00232596,2016,140,165,305,1/1/2008,2008,1,Phase 3,1,y,y,"1 publication reporting pooled analysis, result from clic gov are recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Placebo,18-75,n,75,>/75,Brazil,2,"North America
South America
",N
68,NCT00232596,2016,140,165,305,1/1/2008,2008,1,Phase 3,1,y,y,"1 publication reporting pooled analysis, result from clic gov are recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Placebo,18-75,n,75,>/75,Canada,2,"North America
South America
",N
68,NCT00232596,2016,140,165,305,1/1/2008,2008,1,Phase 3,1,y,y,"1 publication reporting pooled analysis, result from clic gov are recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Placebo,18-75,n,75,>/75,Mexico,2,"North America
South America
",N
68,NCT00232596,2016,140,165,305,1/1/2008,2008,1,Phase 3,1,y,y,"1 publication reporting pooled analysis, result from clic gov are recorded",R,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Placebo,18-75,n,75,>/75,,2,"North America
South America
",N
69,NCT00609245,2017,3,10,13,12/1/2008,2008,1,Phase 4,0,n,y,,O,Effect of Small Changes in Plasma Valproic Acid Concentration on the Photoparoxysmal Response,Vanderbilt University Medical Center,2,Valproic Acid | Placebo,15–65,y,65,65-<75,United States of America,1,North America,n
70,NCT00318929,2018,11,3,14,1/1/2008,2008,1,,0,n,y,,O,Tolerability and Efficacy of Depakote-ER in the Elderly,Virginia Commonwealth University,2,Divalproex Sodium Extended-Release Tablets,60 years and older,n,nil,>/75,United States of America,1,North America,n
71,NCT01318408,2018,13,11,24,3/1/2008,2008,3,Phase 4,0,n,y,,O,"A Prospective, Phase 4, Open-Label, Twelve-Week Study to Examine the Cognitive Impact and Tolerability of Levetiracetam (Keppra) in Elderly Patients With Seizures of Partial Onset",Drexel University,2,Levetiracetam,60–90,n,90,>/75,United States of America,1,North America,n
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,United States of America,2,"North America
South America
Europe
Asia",Y
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,Argentina,2,"North America
South America
Europe
Asia",Y
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,Brazil,2,"North America
South America
Europe
Asia",Y
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,Chile,2,"North America
South America
Europe
Asia",Y
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,Germany,2,"North America
South America
Europe
Asia",Y
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,India,2,"North America
South America
Europe
Asia",Y
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,"Korea, Republic of",2,"North America
South America
Europe
Asia",Y
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,Malaysia,2,"North America
South America
Europe
Asia",Y
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,Puerto Rico,2,"North America
South America
Europe
Asia",Y
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,Russian Federation,2,"North America
South America
Europe
Asia",Y
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,Ukraine,2,"North America
South America
Europe
Asia",Y
72,NCT00104416,Biton 2010,73,70,143,7/1/2008,2008,1,Phase 3,1,y,n,,R,"A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures",GlaxoSmithKline,1,lamotrigine (LAMICTAL) extended-release | Placebo,13 years and older,y,nil,>/75,,2,"North America
South America
Europe
Asia",Y
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,Australia,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,Belgium,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,France,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,Germany,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,Hungary,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,Israel,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,Poland,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,Russian Federation,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,South Africa,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,Spain,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,United Kingdom of Great Britain and Northern Ireland,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,Ukraine,2,"Oceania
Europe
Africa
North America",N
73,NCT00235755,Brodie 2010,258,280,538,4/1/2008,2008,1,Phase 3,4,y,y,"4 publications,2 of which are non relevant 1 with pooled analysis, only study which is unique to clinical trial ID recorded",R,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures",GlaxoSmithKline,1,Retigabine | Retigabine | Placebo,18-75,n,75,>/75,United States of America,2,"Oceania
Europe
Africa
North America",N
74,NCT00355082,French 2012,91,132,223,11/1/2008,2008,1,Phase 3,2,y,y,"2 publication, only original publication is recorded",R,"A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures",GlaxoSmithKline,1,"lamotrigine, 300 mg/day | lamotrigine, 250 mg/day",13 years and older,y,nil,>/75,United States of America,2,"North America
South America
Asia
Europe",Y
74,NCT00355082,French 2012,91,132,223,11/1/2008,2008,1,Phase 3,2,y,y,"2 publication, only original publication is recorded",R,"A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures",GlaxoSmithKline,1,"lamotrigine, 300 mg/day | lamotrigine, 250 mg/day",13 years and older,y,nil,>/75,Argentina,2,"North America
South America
Asia
Europe",Y
74,NCT00355082,French 2012,91,132,223,11/1/2008,2008,1,Phase 3,2,y,y,"2 publication, only original publication is recorded",R,"A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures",GlaxoSmithKline,1,"lamotrigine, 300 mg/day | lamotrigine, 250 mg/day",13 years and older,y,nil,>/75,Chile,2,"North America
South America
Asia
Europe",Y
74,NCT00355082,French 2012,91,132,223,11/1/2008,2008,1,Phase 3,2,y,y,"2 publication, only original publication is recorded",R,"A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures",GlaxoSmithKline,1,"lamotrigine, 300 mg/day | lamotrigine, 250 mg/day",13 years and older,y,nil,>/75,Costa Rica,2,"North America
South America
Asia
Europe",Y
74,NCT00355082,French 2012,91,132,223,11/1/2008,2008,1,Phase 3,2,y,y,"2 publication, only original publication is recorded",R,"A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures",GlaxoSmithKline,1,"lamotrigine, 300 mg/day | lamotrigine, 250 mg/day",13 years and older,y,nil,>/75,"Korea, Republic of",2,"North America
South America
Asia
Europe",Y
74,NCT00355082,French 2012,91,132,223,11/1/2008,2008,1,Phase 3,2,y,y,"2 publication, only original publication is recorded",R,"A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures",GlaxoSmithKline,1,"lamotrigine, 300 mg/day | lamotrigine, 250 mg/day",13 years and older,y,nil,>/75,Puerto Rico,2,"North America
South America
Asia
Europe",Y
74,NCT00355082,French 2012,91,132,223,11/1/2008,2008,1,Phase 3,2,y,y,"2 publication, only original publication is recorded",R,"A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures",GlaxoSmithKline,1,"lamotrigine, 300 mg/day | lamotrigine, 250 mg/day",13 years and older,y,nil,>/75,Russian Federation,2,"North America
South America
Asia
Europe",Y
74,NCT00355082,French 2012,91,132,223,11/1/2008,2008,1,Phase 3,2,y,y,"2 publication, only original publication is recorded",R,"A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures",GlaxoSmithKline,1,"lamotrigine, 300 mg/day | lamotrigine, 250 mg/day",13 years and older,y,nil,>/75,Ukraine,2,"North America
South America
Asia
Europe",Y
74,NCT00355082,French 2012,91,132,223,11/1/2008,2008,1,Phase 3,2,y,y,"2 publication, only original publication is recorded",R,"A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures",GlaxoSmithKline,1,"lamotrigine, 300 mg/day | lamotrigine, 250 mg/day",13 years and older,y,nil,>/75,,2,"North America
South America
Asia
Europe",Y
75,NCT00326612,holsti 2010,46,46,92,12/1/2008,2008,3,Phase 2,1,y,y,,O,Intranasal Midazolam Versus Rectal Diazepam for the Home Treatment of Seizure Activity in Pediatric Patients With Epilepsy,University of Utah,2,Midazolam | Diazepam,up to 17 years,y,17,</18,United States of America,1,North America,n
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,Austria,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,Belgium,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,czechiaia,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,Germany,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,Hong Kong,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,India,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,Italy,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,"Korea, Republic of",3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,Norway,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,Russian Federation,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,Singapore,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,South Africa,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,Sweden,3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,"Taiwan, Province of China",3,"Europe
Asia
Africa",Y
76,NCT00504881,Kwan 2013,250,230,480,12/1/2008,2008,1,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (__‰ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.",UCB Pharma,1,Placebo | Brivaracetam,16-70,y,70,65-<75,Ukraine,3,"Europe
Asia
Africa",Y
77,NCT00896987,Lee 2011,42,31,73,12/1/2008,2008,3,Phase 4,1,y,n,,O,"An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine or Carbamazepine for Cognitive Function as Initial Monotherapy in Adult Untreated Epilepsies","Korea, Republic ofn Epilepsy Society",2,lamotrigine (Lamictal) | Carbamazepine (Tegretol),16-60,y,60,55-<65,"Korea, Republic of",4,Asia,n
79,NCT00407797,2011,60,76,136,8/1/2009,2009,3,Phase 4,0,n,y,,O,"Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial. A Phase IV Open-Label Trial Using 150,300, 600 mg/Day Of Pregabalin",Pfizer,1,Pregabalin,18 years and older,n,nil,>/75,Mexico,3,North America,n
80,NCT00603473,2011,49,40,89,12/1/2009,2009,3,Phase 3,0,n,y,,O,"An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Patients With Partial Seizures When Other Antiepileptics Do Not Provide Satisfactory Effects",Pfizer,1,gabapentin,3_15,y,15,</18,Japan,4,Asia,n
81,NCT01127165,2012,65,60,125,7/1/2009,2009,3,Phase 4,0,n,y,,O,A Multi-center Comparative Trial of Low and High Dose Zonisamide in Children as Monotherapy,Eisai Inc.,1,zonisamide low dose group | zonisamide high dose group,2–15,y,15,</18,"Korea, Republic of",4,Asia,n
82,NCT01127256,2012,98,102,200,7/1/2009,2009,3,Phase 4,0,n,y,,O,Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation,Eisai Inc.,1,zonisamide | carbamazepine,15 years and older,y,nil,>/75,"Korea, Republic of",4,Asia,n
83,NCT00292461,2013,31,33,64,9/1/2009,2009,3,Phase 3,0,n,y,,O,"A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures",Eisai Inc.,1,Zonisamide | Lamotrigine,16-70,y,70,65-<75,"Taiwan, Province of China",4,Asia,n
83,NCT00292461,2013,31,33,64,9/1/2009,2009,3,Phase 3,0,n,y,,O,"A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures",Eisai Inc.,1,Zonisamide | Lamotrigine,16-70,y,70,65-<75,China,4,Asia,n
84,NCT00334958,2013,167,189,356,5/1/2009,2009,1,Phase 3,0,n,y,,R,"A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures",Eisai Inc.,1,Placebo | Rufinamide,12_80,y,80,>/75,United States of America,1,North America,N
85,NCT00849212,2013,16,14,30,11/1/2009,2009,1,Phase 2,0,n,y,,O,"A Phase II, Open-label, Ascending High-dose, add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)",Eisai Inc.,1,E2007,20-64,n,64,55-<65,Japan,4,Asia,n
86,NCT00594945,2014,7,2,9,6/1/2009,2009,1,Phase 2,0,n,y,,O,"A Phase 2a, Open-label,Proof -Of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures",Jazz Pharmaceuticals,1,Clonazepam,18-65,n,65,65-<75,United States of America,2,"North America
Europe",n
86,NCT00594945,2014,7,2,9,6/1/2009,2009,1,Phase 2,0,n,y,,O,"A Phase 2a, Open-label,Proof -Of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures",Jazz Pharmaceuticals,1,Clonazepam,18-65,n,65,65-<75,Finland,2,"North America
Europe",n
87,NCT00900237,2014,7,7,14,2/1/2009,2009,1,Phase 1,0,n,y,,O,"A Phase I, Single Centre, Open, Randomised, Parallel Study to Evaluate the Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine in Healthy Subject",Bial - Portela C S.A.,1,Eslicarbazepine acetate | Oxcarbazepine,18-55,n,55,55-<65,Belgium,3,Europe,n
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Australia,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Croatia,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,czechiaia,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Estonia,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Finland,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Germany,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Hungary,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Lithuania,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Poland,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Romania,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Russian Federation,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Serbia,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,Ukraine,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,,3,"Oceania
Europe",N
88,NCT00692003,2017,3,3,6,1/9/2009,2009,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_65,y,65,65-<75,,3,"Oceania
Europe",N
89,NCT00395694,2018,54,48,102,3/26/2009,2009,3,Phase 3,0,n,y,,O,Clinical Evaluation of BW430C in Epilepsy<Phase III Study>,GlaxoSmithKline,1,lamictal,2–65,y,65,55-<65,Japan,4,Asia,n
89,NCT00395694,2018,54,48,102,3/26/2009,2009,3,Phase 3,0,n,y,,O,Clinical Evaluation of BW430C in Epilepsy<Phase III Study>,GlaxoSmithKline,1,lamictal,2–65,y,65,55-<65,,4,Asia,n
90,NCT00735527,Arya 2011,77,64,141,4/1/2009,2009,1,Phase 3,1,y,n,,O,Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial,"All India Institute of Medical Sciences, New Delhi",2,Lorazepam | Lorazepam,6_14,y,14,</18,India,3,Asia,n
91,NCT00571155,Bahr 2012,22,8,30,8/1/2009,2009,1,Phase 4,1,y,0,,O,Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study),University Hospital Tuebingen,2,levetiracetam,18 years and older,n,nil,>/75,Germany,3,Europe,n
92,NCT00464269,Biton 2014,195,201,396,1/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam 2.5 mg | Brivaracetam 10 mg | Brivaracetam 25 mg,16-70,y,70,65-<75,United States of America,2,"North America
Oceania
South America
",Y
92,NCT00464269,Biton 2014,195,201,396,1/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam 2.5 mg | Brivaracetam 10 mg | Brivaracetam 25 mg,16-70,y,70,65-<75,Australia,2,"North America
Oceania
South America
",Y
92,NCT00464269,Biton 2014,195,201,396,1/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam 2.5 mg | Brivaracetam 10 mg | Brivaracetam 25 mg,16-70,y,70,65-<75,Brazil,2,"North America
Oceania
South America
",Y
92,NCT00464269,Biton 2014,195,201,396,1/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam 2.5 mg | Brivaracetam 10 mg | Brivaracetam 25 mg,16-70,y,70,65-<75,Canada,2,"North America
Oceania
South America
",Y
92,NCT00464269,Biton 2014,195,201,396,1/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam 2.5 mg | Brivaracetam 10 mg | Brivaracetam 25 mg,16-70,y,70,65-<75,Mexico,2,"North America
Oceania
South America
",Y
93,NCT00419094,Chung 2012,96,132,228,9/1/2009,2009,1,Phase 3,1,y,y,"safety and eficacy demographics are reported and population are overlap, safety analysis demographic are recorded as it includes all patients",R,"A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures",UCB Pharma,1,Keppra XR | Keppra XR,12_75,y,75,>/75,United States of America,2,"North America
Europe",Y
93,NCT00419094,Chung 2012,96,132,228,9/1/2009,2009,1,Phase 3,1,y,y,"safety and eficacy demographics are reported and population are overlap, safety analysis demographic are recorded as it includes all patients",R,"A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures",UCB Pharma,1,Keppra XR | Keppra XR,12_75,y,75,>/75,Mexico,2,"North America
Europe",Y
93,NCT00419094,Chung 2012,96,132,228,9/1/2009,2009,1,Phase 3,1,y,y,"safety and eficacy demographics are reported and population are overlap, safety analysis demographic are recorded as it includes all patients",R,"A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures",UCB Pharma,1,Keppra XR | Keppra XR,12_75,y,75,>/75,Poland,2,"North America
Europe",Y
93,NCT00419094,Chung 2012,96,132,228,9/1/2009,2009,1,Phase 3,1,y,y,"safety and eficacy demographics are reported and population are overlap, safety analysis demographic are recorded as it includes all patients",R,"A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures",UCB Pharma,1,Keppra XR | Keppra XR,12_75,y,75,>/75,Russian Federation,2,"North America
Europe",Y
94,NCT00542802,Consoli 2012,58,48,106,6/1/2009,2009,3,Phase 3,1,y,n,,O,"Multicenter, Comparative, Randomized, Open Trial to Evaluate Efficacy and Safety of Levetiracetam Versus Carbamazepine in Post Stroke Late Onset Crisis",Scienze Neurologiche Ospedaliere,2,Levetiracetam | Carbamazepine,18 years and older,n,nil,>/75,Italy,3,Europe,n
95,NCT00655551,Fountain 2013,51,49,100,9/1/2009,2009,3,Phase 3,1,y,y,,O,"A Multicenter, Open-label Trial to Assess the Safety and Tolerability of a Single Intravenous Loading Dose of Lacosamide Followed by Oral Lacosamide Maintenance as Adjunctive Therapy in Subjects With Partial-onset Seizures",UCB Pharma,1,lacosamide | lacosamide | lacosamide,16-60,y,60,55-<65,United States of America,1,North America,n
96,NCT00242606,rosennow 2012,215,194,409,1/1/2009,2009,3,Phase 3,1,y,n,,O,"Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study",Philipps University Marburg Medical Center,2,Lamotrigine | Levetiracetam,12 years and older,y,nil,>/75,Germany,3,Europe,n
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,Belgium,3,"Europe
Asia
",Y
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,Finland,3,"Europe
Asia
",Y
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,France,3,"Europe
Asia
",Y
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,Germany,3,"Europe
Asia
",Y
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,Hungary,3,"Europe
Asia
",Y
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,India,3,"Europe
Asia
",Y
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,Italy,3,"Europe
Asia
",Y
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,Netherlands,3,"Europe
Asia
",Y
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,Poland,3,"Europe
Asia
",Y
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,Spain,3,"Europe
Asia
",Y
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,Switzerland,3,"Europe
Asia
",Y
97,NCT00490035,Ryvlin 2014,227,171,398,2/1/2009,2009,1,Phase 3,11,y,y,"11 publication, only study which is unique to clinic trial ID recorded as others include pooled data,",R,"A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Brivaracetam,16-70,y,70,65-<75,United Kingdom of Great Britain and Northern Ireland,3,"Europe
Asia
",Y
98,NCT00535392,2011,19,14,33,2/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (4 - 16 Years Old) With Epilepsy.",UCB Pharma,1,Levetiracetam,4_16,y,16,</18,United States of America,2,"North America
Europe
",n
98,NCT00535392,2011,19,14,33,2/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (4 - 16 Years Old) With Epilepsy.",UCB Pharma,1,Levetiracetam,4_16,y,16,</18,Belgium,2,"North America
Europe
",n
98,NCT00535392,2011,19,14,33,2/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (4 - 16 Years Old) With Epilepsy.",UCB Pharma,1,Levetiracetam,4_16,y,16,</18,France,2,"North America
Europe
",n
98,NCT00535392,2011,19,14,33,2/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (4 - 16 Years Old) With Epilepsy.",UCB Pharma,1,Levetiracetam,4_16,y,16,</18,Germany,2,"North America
Europe
",n
98,NCT00535392,2011,19,14,33,2/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (4 - 16 Years Old) With Epilepsy.",UCB Pharma,1,Levetiracetam,4_16,y,16,</18,Mexico,2,"North America
Europe
",n
98,NCT00535392,2011,19,14,33,2/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (4 - 16 Years Old) With Epilepsy.",UCB Pharma,1,Levetiracetam,4_16,y,16,</18,Turkey,2,"North America
Europe
",n
100,NCT00772603,2014,164,202,366,11/1/2010,2010,1,Phase 3,0,n,y,,R,Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"Supernus Pharmaceuticals, Inc.",1,Placebo | 2400mg SPN-804 | 1200mg SPN-804,18-65,n,65,65-<75,United States of America,2,"North America
Europe
",N
100,NCT00772603,2014,164,202,366,11/1/2010,2010,1,Phase 3,0,n,y,,R,Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"Supernus Pharmaceuticals, Inc.",1,Placebo | 2400mg SPN-804 | 1200mg SPN-804,18-65,n,65,65-<75,Bulgaria,2,"North America
Europe
",N
100,NCT00772603,2014,164,202,366,11/1/2010,2010,1,Phase 3,0,n,y,,R,Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"Supernus Pharmaceuticals, Inc.",1,Placebo | 2400mg SPN-804 | 1200mg SPN-804,18-65,n,65,65-<75,Canada,2,"North America
Europe
",N
100,NCT00772603,2014,164,202,366,11/1/2010,2010,1,Phase 3,0,n,y,,R,Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"Supernus Pharmaceuticals, Inc.",1,Placebo | 2400mg SPN-804 | 1200mg SPN-804,18-65,n,65,65-<75,Croatia,2,"North America
Europe
",N
100,NCT00772603,2014,164,202,366,11/1/2010,2010,1,Phase 3,0,n,y,,R,Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"Supernus Pharmaceuticals, Inc.",1,Placebo | 2400mg SPN-804 | 1200mg SPN-804,18-65,n,65,65-<75,Mexico,2,"North America
Europe
",N
100,NCT00772603,2014,164,202,366,11/1/2010,2010,1,Phase 3,0,n,y,,R,Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"Supernus Pharmaceuticals, Inc.",1,Placebo | 2400mg SPN-804 | 1200mg SPN-804,18-65,n,65,65-<75,Poland,2,"North America
Europe
",N
100,NCT00772603,2014,164,202,366,11/1/2010,2010,1,Phase 3,0,n,y,,R,Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"Supernus Pharmaceuticals, Inc.",1,Placebo | 2400mg SPN-804 | 1200mg SPN-804,18-65,n,65,65-<75,Romania,2,"North America
Europe
",N
100,NCT00772603,2014,164,202,366,11/1/2010,2010,1,Phase 3,0,n,y,,R,Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"Supernus Pharmaceuticals, Inc.",1,Placebo | 2400mg SPN-804 | 1200mg SPN-804,18-65,n,65,65-<75,Russian Federation,2,"North America
Europe
",N
100,NCT00772603,2014,164,202,366,11/1/2010,2010,1,Phase 3,0,n,y,,R,Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures,"Supernus Pharmaceuticals, Inc.",1,Placebo | 2400mg SPN-804 | 1200mg SPN-804,18-65,n,65,65-<75,,2,"North America
Europe
",N
101,NCT00505934,2015,12,7,19,3/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (1 Month- 4 Years Old) With Epilepsy",UCB Pharma,1,Levetiracetam,1 month to 4 years,y,4,</18,United States of America,2,"North America
Europe
",n
101,NCT00505934,2015,12,7,19,3/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (1 Month- 4 Years Old) With Epilepsy",UCB Pharma,1,Levetiracetam,1 month to 4 years,y,4,</18,Belgium,2,"North America
Europe
",n
101,NCT00505934,2015,12,7,19,3/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (1 Month- 4 Years Old) With Epilepsy",UCB Pharma,1,Levetiracetam,1 month to 4 years,y,4,</18,France,2,"North America
Europe
",n
101,NCT00505934,2015,12,7,19,3/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (1 Month- 4 Years Old) With Epilepsy",UCB Pharma,1,Levetiracetam,1 month to 4 years,y,4,</18,Germany,2,"North America
Europe
",n
101,NCT00505934,2015,12,7,19,3/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (1 Month- 4 Years Old) With Epilepsy",UCB Pharma,1,Levetiracetam,1 month to 4 years,y,4,</18,Mexico,2,"North America
Europe
",n
101,NCT00505934,2015,12,7,19,3/1/2010,2010,1,Phase 2,0,n,y,,O,"Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (1 Month- 4 Years Old) With Epilepsy",UCB Pharma,1,Levetiracetam,1 month to 4 years,y,4,</18,Turkey,2,"North America
Europe
",n
102,NCT00961441,2015,11,14,25,3/1/2010,2010,1,Phase 2,0,n,y,,O,"An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy",UCB Pharma,1,Keppra XR,12_55,y,55,55-<65,United States of America,1,North America,n
103,NCT00516139,2017,62,59,121,7/1/2010,2010,1,Phase 3,0,n,y,,O,Lamotrigine Extended-Release in Elderly Patients With Epilepsy,GlaxoSmithKline,1,Lamotrigine,65 and older,n,nil,>/75,United States of America,1,North America,n
104,NCT00887861,2017,20,15,35,8/1/2010,2010,1,Phase 2,0,n,y,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Parallel-group Study of BGG492 as Monotherapy in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery",Novartis,1,"Investigational new drug, company code: BGG492 | Placebo",18-65,n,65,65-<75,Germany,3,Europe,N
105,NCT00698581,Arnold 2018,47,41,88,2/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,United States of America,2,"North America
Oceania
Europe",Y
105,NCT00698581,Arnold 2018,47,41,88,2/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,Australia,2,"North America
Oceania
Europe",Y
105,NCT00698581,Arnold 2018,47,41,88,2/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,Belgium,2,"North America
Oceania
Europe",Y
105,NCT00698581,Arnold 2018,47,41,88,2/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,Canada,2,"North America
Oceania
Europe",Y
105,NCT00698581,Arnold 2018,47,41,88,2/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,czechiaia,2,"North America
Oceania
Europe",Y
105,NCT00698581,Arnold 2018,47,41,88,2/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,Germany,2,"North America
Oceania
Europe",Y
105,NCT00698581,Arnold 2018,47,41,88,2/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,Sweden,2,"North America
Oceania
Europe",Y
106,NCT00699283,Arnold 2018,24,38,62,3/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,United States of America,2,"North America
Europe",Y
106,NCT00699283,Arnold 2018,24,38,62,3/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,France,2,"North America
Europe",Y
106,NCT00699283,Arnold 2018,24,38,62,3/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,Germany,2,"North America
Europe",Y
106,NCT00699283,Arnold 2018,24,38,62,3/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,Hungary,2,"North America
Europe",Y
106,NCT00699283,Arnold 2018,24,38,62,3/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,Italy,2,"North America
Europe",Y
106,NCT00699283,Arnold 2018,24,38,62,3/1/2010,2010,1,Phase 3,1,y,y,,R,"An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.",UCB Pharma,1,Brivaracetam | Brivaracetam,16-75,y,75,>/75,Spain,2,"North America
Europe",Y
107,NCT00753493,Clark 2013,7,13,20,8/1/2010,2010,1,Phase 1,1,y,n,,O,Phase I Pharmacokinetic and Safety Study of Intravenous Topiramate in Adult Patients,University of Minnesota - Clinical and Translational Science Institute,2,intravenous topiramate,18 years and older,n,nil,>/75,United States of America,1,North America,n
108,NCT00699972,French 2012,188,200,388,11/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12_99,y,99,>/75,United States of America,2,"North America
South America

",Y
108,NCT00699972,French 2012,188,200,388,11/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12_99,y,99,>/75,Argentina,2,"North America
South America

",Y
108,NCT00699972,French 2012,188,200,388,11/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12_99,y,99,>/75,Canada,2,"North America
South America

",Y
108,NCT00699972,French 2012,188,200,388,11/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12_99,y,99,>/75,Chile,2,"North America
South America

",Y
108,NCT00699972,French 2012,188,200,388,11/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12_99,y,99,>/75,Mexico,2,"North America
South America

",Y
108,NCT00699972,French 2012,188,200,388,11/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12_99,y,99,>/75,,2,"North America
South America

",Y
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Australia,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Belgium,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Croatia,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Finland,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Germany,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Hong Kong,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,India,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Italy,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,"Korea, Republic of",2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Lithuania,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Mexico,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Russian Federation,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Sweden,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,Thailand,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,United States of America,2,"Oceania
Europe
Asia
North America
",N
109,NCT00740623,Halford 2011,269,278,547,4/1/2010,2010,1,Phase 3,1,y,n,,R,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.","SK Life Science, Inc.",1,Carisbamate | placebo | Carisbamate,16 years and older,y,nil,>/75,,2,"Oceania
Europe
Asia
North America
",N
110,NCT01463033,Klein 2012,99,27,126,2/1/2010,2010,1,Phase 2,1,y,y,,O,Pilot: Levetiracetam to Prevent Post-Traumatic Epilepsy,Children's Research Institute,2,Levetiracetam,6 years and older,y,nil,>/75,United States of America,1,North America,n
111,NCT00700310,Krauss 2012,345,361,706,1/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,perampanel | perampanel | perampanel | Placebo,12-120,y,120,>/75,Germany,3,"Europe
Asia
",Y
111,NCT00700310,Krauss 2012,345,361,706,1/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,perampanel | perampanel | perampanel | Placebo,12-120,y,120,>/75,Bulgaria,3,"Europe
Asia
",Y
111,NCT00700310,Krauss 2012,345,361,706,1/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,perampanel | perampanel | perampanel | Placebo,12-120,y,120,>/75,Portugal,3,"Europe
Asia
",Y
111,NCT00700310,Krauss 2012,345,361,706,1/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,perampanel | perampanel | perampanel | Placebo,12-120,y,120,>/75,Lithuania,3,"Europe
Asia
",Y
111,NCT00700310,Krauss 2012,345,361,706,1/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,perampanel | perampanel | perampanel | Placebo,12-120,y,120,>/75,India,3,"Europe
Asia
",Y
111,NCT00700310,Krauss 2012,345,361,706,1/1/2010,2010,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,perampanel | perampanel | perampanel | Placebo,12-120,y,120,>/75,China,3,"Europe
Asia
",Y
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Belgium,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Bulgaria,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,China,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Colombia,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,czechiaia,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Estonia,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Finland,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,France,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Germany,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Hong Kong,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Hungary,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,India,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Ireland,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Italy,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,"Korea, Republic of",3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Latvia,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Lithuania,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Mexico,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Netherlands,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Norway,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Portugal,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Romania,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Singapore,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Slovakia,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Spain,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Sweden,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,"Taiwan, Province of China",3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,Thailand,3,"Europe
Asia
South America
Europe
North America",N
112,NCT00280059,Kwan 2011,349,311,660,4/1/2010,2010,1,Phase 3,1,y,y,,R,"A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures",Pfizer,1,Pregabalin | Lamotrigine,16 years and older,y,nil,>/75,United Kingdom of Great Britain and Northern Ireland,3,"Europe
Asia
South America
Europe
North America",N
113,NCT01224457,Lee 2012,25,19,44,5/1/2010,2010,1,,1,y,n,,O,"Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korea, Republic ofn Neonatal Seizure Patients.",Yonsei University,2,Phenobarbital,up to 1 year,y,1,</18,"Korea, Republic of",4,Asia,n
114,NCT00518713,Ng 2011,144,94,238,4/1/2010,2010,1,Phase 3,2,y,y,"2 publication, 1 with OL , original study recorded",R,"Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome",Lundbeck LLC,1,Clobazam Low Dose | Clobazam Medium Dose | Clobazam High Dose | Placebo,2_60,y,60,55-<65,United States of America,2,"North America
Oceania
Europe
Asia
",Y
114,NCT00518713,Ng 2011,144,94,238,4/1/2010,2010,1,Phase 3,2,y,y,"2 publication, 1 with OL , original study recorded",R,"Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome",Lundbeck LLC,1,Clobazam Low Dose | Clobazam Medium Dose | Clobazam High Dose | Placebo,2_60,y,60,55-<65,Australia,2,"North America
Oceania
Europe
Asia
",Y
114,NCT00518713,Ng 2011,144,94,238,4/1/2010,2010,1,Phase 3,2,y,y,"2 publication, 1 with OL , original study recorded",R,"Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome",Lundbeck LLC,1,Clobazam Low Dose | Clobazam Medium Dose | Clobazam High Dose | Placebo,2_60,y,60,55-<65,Belarus,2,"North America
Oceania
Europe
Asia
",Y
114,NCT00518713,Ng 2011,144,94,238,4/1/2010,2010,1,Phase 3,2,y,y,"2 publication, 1 with OL , original study recorded",R,"Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome",Lundbeck LLC,1,Clobazam Low Dose | Clobazam Medium Dose | Clobazam High Dose | Placebo,2_60,y,60,55-<65,India,2,"North America
Oceania
Europe
Asia
",Y
114,NCT00518713,Ng 2011,144,94,238,4/1/2010,2010,1,Phase 3,2,y,y,"2 publication, 1 with OL , original study recorded",R,"Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome",Lundbeck LLC,1,Clobazam Low Dose | Clobazam Medium Dose | Clobazam High Dose | Placebo,2_60,y,60,55-<65,Lithuania,2,"North America
Oceania
Europe
Asia
",Y
115,NCT01140867,2011,69,52,121,3/1/2011,2011,1,Phase 4,0,n,y,,O,"A Korea, Republic ofn Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy",Eisai Inc.,1,zonisamide,15 years and older,y,nil,>/75,"Korea, Republic of",4,Asia,n
116,NCT01355068,2011,25,1,26,6/1/2011,2011,1,Phase 1,0,n,y,,O,"An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study of Epanutin Infatabs 50 mg (Sourced From Germany) Verses Dilantin Infatabs 50 mg (Sourced From Australia) in Healthy Subjects",Pfizer,1,Epanutin Infatabs (Phenytoin) | Dilantin Infatabs (Phenytoin),21-55,n,55,55-<65,Singapore,4,Asia,n
117,NCT00596466,2012,37,38,75,12/1/2011,2011,1,Phase 3,0,n,y,,O,An Open-Label Multicenter Extension Study To Determine Long Term Safety And Efficacy Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures,Pfizer,1,pregabalin,18 years and older,n,nil,>/75,United States of America,2,"North America
Asia
Europe",n
117,NCT00596466,2012,37,38,75,12/1/2011,2011,1,Phase 3,0,n,y,,O,An Open-Label Multicenter Extension Study To Determine Long Term Safety And Efficacy Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures,Pfizer,1,pregabalin,18 years and older,n,nil,>/75,czechiaia,2,"North America
Asia
Europe",n
117,NCT00596466,2012,37,38,75,12/1/2011,2011,1,Phase 3,0,n,y,,O,An Open-Label Multicenter Extension Study To Determine Long Term Safety And Efficacy Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures,Pfizer,1,pregabalin,18 years and older,n,nil,>/75,Hong Kong,2,"North America
Asia
Europe",n
117,NCT00596466,2012,37,38,75,12/1/2011,2011,1,Phase 3,0,n,y,,O,An Open-Label Multicenter Extension Study To Determine Long Term Safety And Efficacy Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures,Pfizer,1,pregabalin,18 years and older,n,nil,>/75,Ukraine,2,"North America
Asia
Europe",n
117,NCT00596466,2012,37,38,75,12/1/2011,2011,1,Phase 3,0,n,y,,O,An Open-Label Multicenter Extension Study To Determine Long Term Safety And Efficacy Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures,Pfizer,1,pregabalin,18 years and older,n,nil,>/75,,2,"North America
Asia
Europe",n
118,NCT00566254,2013,108,99,207,3/1/2011,2011,1,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_17,y,17,</18,Belgium,3,"Europe
",Y
118,NCT00566254,2013,108,99,207,3/1/2011,2011,1,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_17,y,17,</18,Estonia,3,"Europe
",Y
118,NCT00566254,2013,108,99,207,3/1/2011,2011,1,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_17,y,17,</18,France,3,"Europe
",Y
118,NCT00566254,2013,108,99,207,3/1/2011,2011,1,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_17,y,17,</18,Hungary,3,"Europe
",Y
118,NCT00566254,2013,108,99,207,3/1/2011,2011,1,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_17,y,17,</18,Italy,3,"Europe
",Y
118,NCT00566254,2013,108,99,207,3/1/2011,2011,1,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_17,y,17,</18,Latvia,3,"Europe
",Y
118,NCT00566254,2013,108,99,207,3/1/2011,2011,1,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_17,y,17,</18,Poland,3,"Europe
",Y
118,NCT00566254,2013,108,99,207,3/1/2011,2011,1,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_17,y,17,</18,Spain,3,"Europe
",Y
118,NCT00566254,2013,108,99,207,3/1/2011,2011,1,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures",Eisai Inc.,1,Zonisamide | Placebo,6_17,y,17,</18,Ukraine,3,"Europe
",Y
120,NCT01364558,2014,19,5,24,4/1/2011,2011,1,Phase 1,0,n,y,,O,"A Three-Period, Three-Treatment, Six-Sequence Randomized Crossover Study of the Bioavailability and Pharmacokinetics of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers"",",University of Minnesota - Clinical and Translational Science Institute,2,Diazepam | Diazepam,18-45,n,45,19-54,United States of America,1,North America,n
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Australia,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Denmark,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,France,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Germany,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Greece,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Hungary,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,India,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Italy,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,"Korea, Republic of",3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Montenegro,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Poland,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Russian Federation,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Serbia,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Slovakia,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,South Africa,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Spain,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Sweden,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,Switzerland,3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,"Taiwan, Province of China",3,"Oceania
Europe
Asia
Africa",Y
121,NCT00848549,2015,346,235,581,11/1/2011,2011,1,Phase 3,0,n,y,,R,"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures",Eisai Inc.,1,Zonisamide | Carbamazepine,18-78,n,78,>/75,United Kingdom of Great Britain and Northern Ireland,3,"Oceania
Europe
Asia
Africa",Y
122,NCT01239212,2015,4,3,7,7/1/2011,2011,1,Phase 1/Phase 2,0,n,y,,O,Pharmacokinetics and Safety of 50 mg/kg IV Levetiracetam (Keppra) in Full Term and Preterm Neonates,"Children's Hospital Medical Center, Cincinnati",2,levetiracetam,up to 30 days,y,0.08,</18,United States of America,1,North America,n
123,NCT01546688,2016,21,30,51,8/1/2011,2011,1,Phase 4,0,n,y,,R,"A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures",Eisai Inc.,1,Zonisamide at targeted daily doses of 100-500 mg/day | Placebo administered to match targeted daily doses of 100-500 mg/day,65 and older,n,nil,>/75,Germany,3,Europe,N
123,NCT01546688,2016,21,30,51,8/1/2011,2011,1,Phase 4,0,n,y,,R,"A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures",Eisai Inc.,1,Zonisamide at targeted daily doses of 100-500 mg/day | Placebo administered to match targeted daily doses of 100-500 mg/day,65 and older,n,nil,>/75,Hungary,3,Europe,N
123,NCT01546688,2016,21,30,51,8/1/2011,2011,1,Phase 4,0,n,y,,R,"A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures",Eisai Inc.,1,Zonisamide at targeted daily doses of 100-500 mg/day | Placebo administered to match targeted daily doses of 100-500 mg/day,65 and older,n,nil,>/75,Italy,3,Europe,N
123,NCT01546688,2016,21,30,51,8/1/2011,2011,1,Phase 4,0,n,y,,R,"A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures",Eisai Inc.,1,Zonisamide at targeted daily doses of 100-500 mg/day | Placebo administered to match targeted daily doses of 100-500 mg/day,65 and older,n,nil,>/75,Netherlands,3,Europe,N
123,NCT01546688,2016,21,30,51,8/1/2011,2011,1,Phase 4,0,n,y,,R,"A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures",Eisai Inc.,1,Zonisamide at targeted daily doses of 100-500 mg/day | Placebo administered to match targeted daily doses of 100-500 mg/day,65 and older,n,nil,>/75,Poland,3,Europe,N
123,NCT01546688,2016,21,30,51,8/1/2011,2011,1,Phase 4,0,n,y,,R,"A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures",Eisai Inc.,1,Zonisamide at targeted daily doses of 100-500 mg/day | Placebo administered to match targeted daily doses of 100-500 mg/day,65 and older,n,nil,>/75,Switzerland,3,Europe,N
123,NCT01546688,2016,21,30,51,8/1/2011,2011,1,Phase 4,0,n,y,,R,"A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures",Eisai Inc.,1,Zonisamide at targeted daily doses of 100-500 mg/day | Placebo administered to match targeted daily doses of 100-500 mg/day,65 and older,n,nil,>/75,United Kingdom of Great Britain and Northern Ireland,3,Europe,N
124,NCT01439438,2017,28,0,28,9/11/2011,2011,1,Phase 1,0,n,y,,O,"Relative Bioavailability Study of Two Formulations of Topiramate 100 mg Coated Tablet in Healthy Male Volunteers, the Test Formulation Produced by Dr. Reddy's Laboratories Ltd. and the Reference Formulation (TopamaxÔÎ) Marked by Janssen-Cilag Farmacê_utica Ltda.A Relative Bioavailability Study of Two Formulations of Topiramate 100 mg Coated Tablet in Healthy Male Volunteers, the Test Formulation Produced by Dr. Reddy's Laboratories Ltd. and the Reference Formulation (TopamaxÔÎ) Marked by Janssen-Cilag Farmacê_utica Ltda.",GlaxoSmithKline,1,Topiramate coated tablet | TopamaxÔÎ coated tablet,18-50,n,50,19-54,Brazil,3,South America,n
125,NCT01146951,2018,36,22,58,8/1/2011,2011,1,Phase 3,0,n,y,,R,"A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients",Eisai Inc.,1,Syndrome | Lennox Gastaut Syndrome,4_30,y,30,19-54,Japan,4,"Asia
",N
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Australia,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Denmark,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,France,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Germany,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Greece,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Hungary,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,India,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Italy,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,"Korea, Republic of",3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Poland,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Russian Federation,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Serbia,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Slovakia,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,South Africa,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Spain,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,Sweden,3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,"Taiwan, Province of China",3,"Oceania
Europe
Asia
Africa
",Y
126,NCT00477295,Baulac 2012,346,235,581,1/1/2011,2011,1,Phase 3,1,y,y,,R,"A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy",Eisai Inc.,1,Zonisamide | Carbamazepine,18-75,n,75,>/75,United Kingdom of Great Britain and Northern Ireland,3,"Oceania
Europe
Asia
Africa
",Y
127,NCT01235403,Baulac 2017,45,55,100,12/1/2011,2011,1,Phase 4,1,y,y,,O,"A Multicenter, Open Label Study to Evaluate the Tolerability, Safety and Efficacy of Lacosamide (200mg - 400mg/Day) as add-on Therapy for Patients With Partial Onset Epilepsy Using a Flexible Dose-escalation Schedule and Individualized Maintenance Doses",UCB Pharma,1,Lacosamide,18 years and older,n,nil,>/75,France,3,Europe,n
128,NCT01147003,Elger 2017,47,46,93,9/1/2011,2011,1,Phase 2,1,y,n,* only core ( RCT) population demographic  recorded,R,"A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures",Novartis,1,"Investigational new drug, company code: BGG492 | Placebo | Investigational new drug, company code: BGG492",18-65,n,65,65-<75,United States of America,2,"North America
Asia
Europe

",Y
128,NCT01147003,Elger 2017,47,46,93,9/1/2011,2011,1,Phase 2,1,y,n,* only core ( RCT) population demographic  recorded,R,"A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures",Novartis,1,"Investigational new drug, company code: BGG492 | Placebo | Investigational new drug, company code: BGG492",18-65,n,65,65-<75,Bulgaria,2,"North America
Asia
Europe

",Y
128,NCT01147003,Elger 2017,47,46,93,9/1/2011,2011,1,Phase 2,1,y,n,* only core ( RCT) population demographic  recorded,R,"A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures",Novartis,1,"Investigational new drug, company code: BGG492 | Placebo | Investigational new drug, company code: BGG492",18-65,n,65,65-<75,Germany,2,"North America
Asia
Europe

",Y
128,NCT01147003,Elger 2017,47,46,93,9/1/2011,2011,1,Phase 2,1,y,n,* only core ( RCT) population demographic  recorded,R,"A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures",Novartis,1,"Investigational new drug, company code: BGG492 | Placebo | Investigational new drug, company code: BGG492",18-65,n,65,65-<75,Hungary,2,"North America
Asia
Europe

",Y
128,NCT01147003,Elger 2017,47,46,93,9/1/2011,2011,1,Phase 2,1,y,n,* only core ( RCT) population demographic  recorded,R,"A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures",Novartis,1,"Investigational new drug, company code: BGG492 | Placebo | Investigational new drug, company code: BGG492",18-65,n,65,65-<75,Italy,2,"North America
Asia
Europe

",Y
128,NCT01147003,Elger 2017,47,46,93,9/1/2011,2011,1,Phase 2,1,y,n,* only core ( RCT) population demographic  recorded,R,"A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures",Novartis,1,"Investigational new drug, company code: BGG492 | Placebo | Investigational new drug, company code: BGG492",18-65,n,65,65-<75,"Korea, Republic of",2,"North America
Asia
Europe

",Y
128,NCT01147003,Elger 2017,47,46,93,9/1/2011,2011,1,Phase 2,1,y,n,* only core ( RCT) population demographic  recorded,R,"A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures",Novartis,1,"Investigational new drug, company code: BGG492 | Placebo | Investigational new drug, company code: BGG492",18-65,n,65,65-<75,Poland,2,"North America
Asia
Europe

",Y
128,NCT01147003,Elger 2017,47,46,93,9/1/2011,2011,1,Phase 2,1,y,n,* only core ( RCT) population demographic  recorded,R,"A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures",Novartis,1,"Investigational new drug, company code: BGG492 | Placebo | Investigational new drug, company code: BGG492",18-65,n,65,65-<75,Slovakia,2,"North America
Asia
Europe

",Y
128,NCT01147003,Elger 2017,47,46,93,9/1/2011,2011,1,Phase 2,1,y,n,* only core ( RCT) population demographic  recorded,R,"A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures",Novartis,1,"Investigational new drug, company code: BGG492 | Placebo | Investigational new drug, company code: BGG492",18-65,n,65,65-<75,Switzerland,2,"North America
Asia
Europe

",Y
128,NCT01147003,Elger 2017,47,46,93,9/1/2011,2011,1,Phase 2,1,y,n,* only core ( RCT) population demographic  recorded,R,"A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures",Novartis,1,"Investigational new drug, company code: BGG492 | Placebo | Investigational new drug, company code: BGG492",18-65,n,65,65-<75,"Taiwan, Province of China",2,"North America
Asia
Europe

",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,Australia,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,Austria,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,Belgium,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,Germany,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,Finland,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,France,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,United Kingdom of Great Britain and Northern Ireland ,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,Greece,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,India,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,Israel,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,Italy,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,Netherlands,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,Russian Federation,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,Sweden,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,United States of America,2,"Oceania
Europe
Asia
North America
Africa",Y
129,NCT00699582,French 2013,186,200,386,1/1/2011,2011,1,Phase 3,4,y,y,"4 publications,3 of which are pooled analysis, only study which is unique to clinical trial ID recorded",R,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures",Eisai Inc.,1,E2007 (perampanel) | E2007 (perampanel) | Placebo,12 years and older,y,nil,>/75,South Africa,2,"Oceania
Europe
Asia
North America
Africa",Y
130,NCT00524030,French 2014,72,89,161,6/1/2011,2011,1,Phase 3,1,y,y,,R,"A Double-Blind, Randomized, Multicenter Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures",Pfizer,1,pregabalin 600 mg/day | pregabalin 150 mg/day,18 years and older,n,nil,>/75,United States of America,2,"North America
Europe
Asia",N
130,NCT00524030,French 2014,72,89,161,6/1/2011,2011,1,Phase 3,1,y,y,,R,"A Double-Blind, Randomized, Multicenter Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures",Pfizer,1,pregabalin 600 mg/day | pregabalin 150 mg/day,18 years and older,n,nil,>/75,czechiaia,2,"North America
Europe
Asia",N
130,NCT00524030,French 2014,72,89,161,6/1/2011,2011,1,Phase 3,1,y,y,,R,"A Double-Blind, Randomized, Multicenter Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures",Pfizer,1,pregabalin 600 mg/day | pregabalin 150 mg/day,18 years and older,n,nil,>/75,Hong Kong,2,"North America
Europe
Asia",N
130,NCT00524030,French 2014,72,89,161,6/1/2011,2011,1,Phase 3,1,y,y,,R,"A Double-Blind, Randomized, Multicenter Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures",Pfizer,1,pregabalin 600 mg/day | pregabalin 150 mg/day,18 years and older,n,nil,>/75,Ukraine,2,"North America
Europe
Asia",N
130,NCT00524030,French 2014,72,89,161,6/1/2011,2011,1,Phase 3,1,y,y,,R,"A Double-Blind, Randomized, Multicenter Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures",Pfizer,1,pregabalin 600 mg/day | pregabalin 150 mg/day,18 years and older,n,nil,>/75,,2,"North America
Europe
Asia",N
131,NCT00884052,Sharpe 2012,9,9,18,10/1/2011,2011,1,Phase 1/Phase 2,1,y,n,,O,Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures,"University of California, San Diego",2,levetiracetam | levetiracetam,up to 14 days,y,0.04,</18,United States of America,1,North America,n
132,NCT01118949,Wechsler 2017,13,36,49,8/1/2011,2011,1,Phase 2,1,y,y,,O,An Open-Label Pilot Study to Assess the Safety of Oral Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy,UCB Pharma,1,Lacosamide,16-65,y,65,65-<75,United States of America,1,North America,n
133,NCT00438451,Werhahn 2015,215,144,359,8/1/2011,2011,1,Phase 4,1,y,y,,R,"A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy.",Johannes Gutenberg University Mainz,1,Levetiracetam | Carbamazepine | Lamotrigine,60 years and older,n,nil,>/75,Germany,3,Europe,Y
134,NCT01407523,2013,8,8,16,2/1/2012,2012,1,Phase 2,0,n,y,,O,"An Open-label, Multicenter Study to Evaluate the Safety of Adjunctive Treatment With Intravenous Levetiracetam (L059 IV) in Epilepsy Patients Aged __‰ 16 Years With Partial Onset Seizures",UCB Pharma,1,Levetiracetam,16 years and older,y,nil,>/75,Japan,4,Asia,n
135,NCT00975715,2014,53,46,99,10/1/2012,2012,1,Phase 2/Phase 3,0,n,y,,R,"A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy",Novartis,1,TRI476 | Placebo to TRI476 | Benzodiazepines,4_14,y,14,</18,Japan,4,"Asia
",N
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,Belgium,3,"Europe
Asia",n
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,Bulgaria,3,"Europe
Asia",n
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,Denmark,3,"Europe
Asia",n
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,France,3,"Europe
Asia",n
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,Germany,3,"Europe
Asia",n
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,Italy,3,"Europe
Asia",n
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,Netherlands,3,"Europe
Asia",n
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,Poland,3,"Europe
Asia",n
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,Russian Federation,3,"Europe
Asia",n
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,Spain,3,"Europe
Asia",n
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,Thailand,3,"Europe
Asia",n
136,NCT01227902,2014,93,110,203,12/1/2012,2012,1,Phase 3,0,n,y,,O,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures",GlaxoSmithKline,1,Retigabine IR,18 years and older,n,nil,>/75,Ukraine,3,"Europe
Asia",n
137,NCT00807989,2015,103,99,202,5/1/2012,2012,1,Phase 4,0,n,y,,O,"An Open Label, Randomized, Multicenter Clinical Trial to Compare the Efficacy and Safety of Lamotrigine / Valproate Coadministration and Carbamazepine as Initial Pharmacotherapy in Epilepsies (Phase _ó£)",Yonsei University,2,Carbamazepine | Lamotrigine/Valproate,16 years and older,y,nil,>/75,"Korea, Republic of",4,Asia,n
138,NCT00916149,2018,12,18,30,10/1/2012,2012,1,,0,n,y,,O,Cognitive Effects of Treatment of Interictal Discharges,Massachusetts General Hospital,2,levetiracetam | Lamotrigine,18-55,n,55,55-<65,United States of America,1,North America,n
139,NCT01405508,2018,49,56,105,7/1/2012,2012,1,Phase 3,0,n,y,,O,"A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy",UCB Pharma,1,Brivaracetam tablets | Brivaracetam bolus | Brivaracetam infusion | Placebo,16-70,y,70,65-<75,United States of America,2,"North America
Europe",n
139,NCT01405508,2018,49,56,105,7/1/2012,2012,1,Phase 3,0,n,y,,O,"A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy",UCB Pharma,1,Brivaracetam tablets | Brivaracetam bolus | Brivaracetam infusion | Placebo,16-70,y,70,65-<75,czechiaia,2,"North America
Europe",n
139,NCT01405508,2018,49,56,105,7/1/2012,2012,1,Phase 3,0,n,y,,O,"A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy",UCB Pharma,1,Brivaracetam tablets | Brivaracetam bolus | Brivaracetam infusion | Placebo,16-70,y,70,65-<75,Germany,2,"North America
Europe",n
139,NCT01405508,2018,49,56,105,7/1/2012,2012,1,Phase 3,0,n,y,,O,"A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy",UCB Pharma,1,Brivaracetam tablets | Brivaracetam bolus | Brivaracetam infusion | Placebo,16-70,y,70,65-<75,Poland,2,"North America
Europe",n
140,NCT01462669,2018,6,10,16,6/27/2012,2012,1,Phase 1,0,n,y,,O,"An Open-label, Randomized, Single Centre, 4-way Crossover Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ezogabine/Retigabine in Healthy Adult Taiwan, Province of Chinaese Subjects",GlaxoSmithKline,1,50mg Ezogabine/retigabine | 100mg Ezogabine/retigabine | 200mg Ezogabine/retigabine | 400mg Ezogabine/retigabine,20-65,n,65,65-<75,"Taiwan, Province of China",4,Asia,n
141,NCT00621478,Chamberlain 2014,155,155,310,5/1/2012,2012,1,Phase 2/Phase 3,2,y,n,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"Use Of Lorazepam For The Treatment Of Pediatric Status Epilepticus: A Randomized, Double-Blinded Trial Of Lorazepam And Diazepam",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),2,lorazepam or diazepam,3_18,y,18,</18,United States of America,2,North America,N
141,NCT00621478,Chamberlain 2014,155,155,310,5/1/2012,2012,1,Phase 2/Phase 3,2,y,n,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"Use Of Lorazepam For The Treatment Of Pediatric Status Epilepticus: A Randomized, Double-Blinded Trial Of Lorazepam And Diazepam",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),2,lorazepam or diazepam,3_18,y,18,</18,Canada,2,North America,N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,United States of America,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Argentina,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Bosnia and Herzegovina,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Bulgaria,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,czechiaia,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Germany,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Hong Kong,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Hungary,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,India,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Malaysia,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Mexico,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Poland,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Puerto Rico,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Romania,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Russian Federation,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Serbia,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Singapore,2,"North America
South America
Europe
Asia
",N
142,NCT01262677,French 2014,154,169,323,8/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures",Pfizer,1,pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | pregabalin | placebo,18 years and older,n,nil,>/75,Thailand,2,"North America
South America
Europe
Asia
",N
143,NCT01091662,Jacobson 2015,83,89,172,11/1/2012,2012,1,Phase 3,1,y,y,,R,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs",Sunovion,1,Eslicarbazepine acetate 1600 mg | Eslicarbazepine acetate 1200 mg,16-70,y,70,65-<75,United States of America,2,"North America
Europe
",Y
143,NCT01091662,Jacobson 2015,83,89,172,11/1/2012,2012,1,Phase 3,1,y,y,,R,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs",Sunovion,1,Eslicarbazepine acetate 1600 mg | Eslicarbazepine acetate 1200 mg,16-70,y,70,65-<75,Bulgaria,2,"North America
Europe
",Y
143,NCT01091662,Jacobson 2015,83,89,172,11/1/2012,2012,1,Phase 3,1,y,y,,R,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs",Sunovion,1,Eslicarbazepine acetate 1600 mg | Eslicarbazepine acetate 1200 mg,16-70,y,70,65-<75,czechiaia,2,"North America
Europe
",Y
143,NCT01091662,Jacobson 2015,83,89,172,11/1/2012,2012,1,Phase 3,1,y,y,,R,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs",Sunovion,1,Eslicarbazepine acetate 1600 mg | Eslicarbazepine acetate 1200 mg,16-70,y,70,65-<75,Serbia,2,"North America
Europe
",Y
143,NCT01091662,Jacobson 2015,83,89,172,11/1/2012,2012,1,Phase 3,1,y,y,,R,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs",Sunovion,1,Eslicarbazepine acetate 1600 mg | Eslicarbazepine acetate 1200 mg,16-70,y,70,65-<75,Ukraine,2,"North America
Europe
",Y
143,NCT01091662,Jacobson 2015,83,89,172,11/1/2012,2012,1,Phase 3,1,y,y,,R,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs",Sunovion,1,Eslicarbazepine acetate 1600 mg | Eslicarbazepine acetate 1200 mg,16-70,y,70,65-<75,,2,"North America
Europe
",Y
144,NCT00437281,Mann 2014,33,32,65,11/1/2012,2012,1,Phase 1/Phase 2,1,y,y,,R,"A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures",Pfizer,1,Placebo | Pregabalin,1 month - 16 years,y,16,</18,United States of America,2,"North America
Asia
",N
144,NCT00437281,Mann 2014,33,32,65,11/1/2012,2012,1,Phase 1/Phase 2,1,y,y,,R,"A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures",Pfizer,1,Placebo | Pregabalin,1 month - 16 years,y,16,</18,"Korea, Republic of",2,"North America
Asia
",N
144,NCT00437281,Mann 2014,33,32,65,11/1/2012,2012,1,Phase 1/Phase 2,1,y,y,,R,"A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures",Pfizer,1,Placebo | Pregabalin,1 month - 16 years,y,16,</18,Mexico,2,"North America
Asia
",N
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,United States of America,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,Australia,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,Austria,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,Canada,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,Denmark,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,France,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,Germany,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,Ireland,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,Italy,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,Poland,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,Puerto Rico,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,Spain,2,"North America
Oceania
Europe
",Y
145,NCT00520741,Wechsler 2014,206,219,425,12/1/2012,2012,1,Phase 3,1,y,y,Safety analysis demographic are recorded as it includes all patients,R,"A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures",UCB Pharma,1,Lacosamide | Lacosamide,16-70,y,70,65-<75,United Kingdom of Great Britain and Northern Ireland,2,"North America
Oceania
Europe
",Y
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Belgium,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Bulgaria,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Colombia,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Costa Rica,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,czechiaia,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,France,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Germany,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Greece,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,India,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Italy,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,"Korea, Republic of",3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Lithuania,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Mexico,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Panama,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Peru,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Philippines,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Russian Federation,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Spain,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,"Taiwan, Province of China",3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Turkey,3,"Europe
Asia
North America
South America",N
146,NCT00537238,Zaccara 2014,245,264,509,5/1/2012,2012,1,Phase 3,1,y,y,,R,"A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures",Pfizer,1,pregabalin | levetiracetam,18 years and older,n,nil,>/75,Venezuela (Bolivarian Republic of),3,"Europe
Asia
North America
South America",N
147,NCT01527513,2014,73,50,123,5/1/2013,2013,1,Phase 2,0,n,y,,R,"Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial",Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Placebo,6_16,y,16,</18,Italy,3,Europe,N
147,NCT01527513,2014,73,50,123,5/1/2013,2013,1,Phase 2,0,n,y,,R,"Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial",Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Placebo,6_16,y,16,</18,Netherlands,3,Europe,N
147,NCT01527513,2014,73,50,123,5/1/2013,2013,1,Phase 2,0,n,y,,R,"Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial",Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Placebo,6_16,y,16,</18,Poland,3,Europe,N
147,NCT01527513,2014,73,50,123,5/1/2013,2013,1,Phase 2,0,n,y,,R,"Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial",Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Placebo,6_16,y,16,</18,Russian Federation,3,Europe,N
147,NCT01527513,2014,73,50,123,5/1/2013,2013,1,Phase 2,0,n,y,,R,"Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial",Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Placebo,6_16,y,16,</18,Ukraine,3,Europe,N
147,NCT01527513,2014,73,50,123,5/1/2013,2013,1,Phase 2,0,n,y,,R,"Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial",Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Placebo,6_16,y,16,</18,,3,Europe,N
148,NCT01063764,2015,41,32,73,10/1/2013,2013,1,Phase 3,1,y,y,study result from clinc trial used as publication in japanese and unable to retrieve,O,"An Open Label, Single-Arm, Multi-Center Study on the Efficacy, Safety and Pharmacokinetics of Levetiracetam in Pediatric Patients (4 to 16 Years) With Partial Seizures Despite Treatment With 1 or 2 Anti-Epileptic Drugs",UCB Pharma,1,Levetiracetam,4_16,y,16,</18,Japan,4,Asia,n
149,NCT01292837,2015,9,4,13,6/1/2013,2013,1,Phase 3,0,n,y,,O,"An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Levetiracetam in Japanese Patients (__‰4 to <16 Years) With Uncontrolled Generalized Tonic-clonic (GTC) Seizures Despite Treatment With 1 or 2 Antiepileptic Drug(s)",UCB Pharma,1,Levetiracetam,4_15,y,15,</18,Japan,4,Asia,n
150,NCT01660672,2016,3,4,7,7/1/2013,2013,1,Phase 1/Phase 2,0,n,y,,O,"A Dose-Escalation, Safety And Feasibility Study Of Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria",University of Rochester,2,LEVETIRACETAM,2-6 years,y,6,</18,Malawi,3,Africa,n
151,NCT01266291,2017,0,1,1,12/1/2013,2013,1,Phase 4,0,n,y,,O,"Sabril for Treatment of Adult Refractory Partial Seizures Symptomatic of Tuberous Sclerosis: An Open Label, Phase IV Prospective Safety and Tolerability Study",University of Pennsylvania,2,vigabatrin,18 years and older,n,nil,>/75,United States of America,1,North America,n
152,NCT01417078,2017,13,18,31,3/1/2013,2013,1,Phase 2,0,n,y,,O,An Open-Label Study to Determine the Pharmacokinetics of a Single Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode for Which Acute Treatment With a Benzodiazepine is Clinically Indicated,Acorda Therapeutics,1,Diazepam,18-65,n,65,65-<75,United States of America,1,North America,n
153,NCT01422720,2017,38,34,72,9/1/2013,2013,1,Phase 3,0,n,y,,O,Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients,Bial - Portela C S.A.,1,Eslicarbazepine Acetate,65 and older,n,nil,>/75,Austria,3,Europe,n
153,NCT01422720,2017,38,34,72,9/1/2013,2013,1,Phase 3,0,n,y,,O,Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients,Bial - Portela C S.A.,1,Eslicarbazepine Acetate,65 and older,n,nil,>/75,Bulgaria,3,Europe,n
153,NCT01422720,2017,38,34,72,9/1/2013,2013,1,Phase 3,0,n,y,,O,Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients,Bial - Portela C S.A.,1,Eslicarbazepine Acetate,65 and older,n,nil,>/75,Croatia,3,Europe,n
153,NCT01422720,2017,38,34,72,9/1/2013,2013,1,Phase 3,0,n,y,,O,Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients,Bial - Portela C S.A.,1,Eslicarbazepine Acetate,65 and older,n,nil,>/75,czechiaia,3,Europe,n
153,NCT01422720,2017,38,34,72,9/1/2013,2013,1,Phase 3,0,n,y,,O,Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients,Bial - Portela C S.A.,1,Eslicarbazepine Acetate,65 and older,n,nil,>/75,France,3,Europe,n
153,NCT01422720,2017,38,34,72,9/1/2013,2013,1,Phase 3,0,n,y,,O,Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients,Bial - Portela C S.A.,1,Eslicarbazepine Acetate,65 and older,n,nil,>/75,Germany,3,Europe,n
153,NCT01422720,2017,38,34,72,9/1/2013,2013,1,Phase 3,0,n,y,,O,Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients,Bial - Portela C S.A.,1,Eslicarbazepine Acetate,65 and older,n,nil,>/75,Poland,3,Europe,n
153,NCT01422720,2017,38,34,72,9/1/2013,2013,1,Phase 3,0,n,y,,O,Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients,Bial - Portela C S.A.,1,Eslicarbazepine Acetate,65 and older,n,nil,>/75,Portugal,3,Europe,n
153,NCT01422720,2017,38,34,72,9/1/2013,2013,1,Phase 3,0,n,y,,O,Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients,Bial - Portela C S.A.,1,Eslicarbazepine Acetate,65 and older,n,nil,>/75,Romania,3,Europe,n
153,NCT01422720,2017,38,34,72,9/1/2013,2013,1,Phase 3,0,n,y,,O,Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients,Bial - Portela C S.A.,1,Eslicarbazepine Acetate,65 and older,n,nil,>/75,Spain,3,Europe,n
153,NCT01422720,2017,38,34,72,9/1/2013,2013,1,Phase 3,0,n,y,,O,Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients,Bial - Portela C S.A.,1,Eslicarbazepine Acetate,65 and older,n,nil,>/75,,3,Europe,n
154,NCT00422422,2018,49,51,100,3/1/2013,2013,1,Phase 2,0,n,y,,O,"Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From __‰1 Month to <16 Years Old With Epilepsy",UCB Pharma,1,Brivaracetam,1month to 16 years,y,16,</18,United States of America,2,"North America
Europe",N
154,NCT00422422,2018,49,51,100,3/1/2013,2013,1,Phase 2,0,n,y,,O,"Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From __‰1 Month to <16 Years Old With Epilepsy",UCB Pharma,1,Brivaracetam,1month to 16 years,y,16,</18,Belgium,2,"North America
Europe",N
154,NCT00422422,2018,49,51,100,3/1/2013,2013,1,Phase 2,0,n,y,,O,"Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From __‰1 Month to <16 Years Old With Epilepsy",UCB Pharma,1,Brivaracetam,1month to 16 years,y,16,</18,czechiaia,2,"North America
Europe",N
154,NCT00422422,2018,49,51,100,3/1/2013,2013,1,Phase 2,0,n,y,,O,"Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From __‰1 Month to <16 Years Old With Epilepsy",UCB Pharma,1,Brivaracetam,1month to 16 years,y,16,</18,Mexico,2,"North America
Europe",N
154,NCT00422422,2018,49,51,100,3/1/2013,2013,1,Phase 2,0,n,y,,O,"Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From __‰1 Month to <16 Years Old With Epilepsy",UCB Pharma,1,Brivaracetam,1month to 16 years,y,16,</18,Poland,2,"North America
Europe",N
154,NCT00422422,2018,49,51,100,3/1/2013,2013,1,Phase 2,0,n,y,,O,"Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From __‰1 Month to <16 Years Old With Epilepsy",UCB Pharma,1,Brivaracetam,1month to 16 years,y,16,</18,Spain,2,"North America
Europe",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,United States of America,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Austria,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Bulgaria,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,czechiaia,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Denmark,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Finland,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,France,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Greece,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Italy,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Mexico,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Romania,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Russian Federation,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Spain,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Switzerland,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,Turkey,2,"North America
Europe
",N
155,NCT00955357,2018,223,233,456,8/1/2013,2013,1,Phase 4,0,n,y,,O,"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,17 years and older,y,nil,>/75,,2,"North America
Europe
",N
156,NCT01494584,2018,4,1,5,4/29/2013,2013,1,Phase 2,0,n,y,,O,"Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome",GlaxoSmithKline,1,ezogabine/retigabine,12–17,y,17,</18,United States of America,1,North America,n
157,NCT01648101,2018,45,30,75,12/23/2013,2013,1,Phase 3,0,n,y,,R,"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures.",GlaxoSmithKline,1,Retigabine 900mg/day | Retigabine 600mg/day | Placebo,18 years and older,n,nil,>/75,Hong Kong,4,Asia,N
157,NCT01648101,2018,45,30,75,12/23/2013,2013,1,Phase 3,0,n,y,,R,"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures.",GlaxoSmithKline,1,Retigabine 900mg/day | Retigabine 600mg/day | Placebo,18 years and older,n,nil,>/75,"Korea, Republic of",4,Asia,N
157,NCT01648101,2018,45,30,75,12/23/2013,2013,1,Phase 3,0,n,y,,R,"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures.",GlaxoSmithKline,1,Retigabine 900mg/day | Retigabine 600mg/day | Placebo,18 years and older,n,nil,>/75,Malaysia,4,Asia,N
157,NCT01648101,2018,45,30,75,12/23/2013,2013,1,Phase 3,0,n,y,,R,"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures.",GlaxoSmithKline,1,Retigabine 900mg/day | Retigabine 600mg/day | Placebo,18 years and older,n,nil,>/75,Philippines,4,Asia,N
157,NCT01648101,2018,45,30,75,12/23/2013,2013,1,Phase 3,0,n,y,,R,"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures.",GlaxoSmithKline,1,Retigabine 900mg/day | Retigabine 600mg/day | Placebo,18 years and older,n,nil,>/75,Singapore,4,Asia,N
157,NCT01648101,2018,45,30,75,12/23/2013,2013,1,Phase 3,0,n,y,,R,"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures.",GlaxoSmithKline,1,Retigabine 900mg/day | Retigabine 600mg/day | Placebo,18 years and older,n,nil,>/75,"Taiwan, Province of China",4,Asia,N
157,NCT01648101,2018,45,30,75,12/23/2013,2013,1,Phase 3,0,n,y,,R,"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures.",GlaxoSmithKline,1,Retigabine 900mg/day | Retigabine 600mg/day | Placebo,18 years and older,n,nil,>/75,Thailand,4,Asia,N
157,NCT01648101,2018,45,30,75,12/23/2013,2013,1,Phase 3,0,n,y,,R,"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures.",GlaxoSmithKline,1,Retigabine 900mg/day | Retigabine 600mg/day | Placebo,18 years and older,n,nil,>/75,,4,Asia,N
158,NCT01721317,2018,1,5,6,6/20/2013,2013,2,Phase 4,0,n,y,,R,"Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets Versus Placebo in the Adjunctive Treatment of Subjects With Partial-Onset Seizures",GlaxoSmithKline,1,Ezogabine/Retigabine IR | Placebo,18 years and older,n,nil,>/75,United States of America,2,"North America
Europe",N
158,NCT01721317,2018,1,5,6,6/20/2013,2013,2,Phase 4,0,n,y,,R,"Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets Versus Placebo in the Adjunctive Treatment of Subjects With Partial-Onset Seizures",GlaxoSmithKline,1,Ezogabine/Retigabine IR | Placebo,18 years and older,n,nil,>/75,Greece,2,"North America
Europe",N
159,NCT01484977,Baulac 2016,46,74,120,12/1/2013,2013,1,Phase 3,1,y,y,,O,"Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures",UCB Pharma,1,Lacosamide,18 years and older,n,nil,>/75,United States of America,2,"North America
Oceania
Europe",n
159,NCT01484977,Baulac 2016,46,74,120,12/1/2013,2013,1,Phase 3,1,y,y,,O,"Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures",UCB Pharma,1,Lacosamide,18 years and older,n,nil,>/75,Australia,2,"North America
Oceania
Europe",n
159,NCT01484977,Baulac 2016,46,74,120,12/1/2013,2013,1,Phase 3,1,y,y,,O,"Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures",UCB Pharma,1,Lacosamide,18 years and older,n,nil,>/75,Bulgaria,2,"North America
Oceania
Europe",n
159,NCT01484977,Baulac 2016,46,74,120,12/1/2013,2013,1,Phase 3,1,y,y,,O,"Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures",UCB Pharma,1,Lacosamide,18 years and older,n,nil,>/75,Denmark,2,"North America
Oceania
Europe",n
159,NCT01484977,Baulac 2016,46,74,120,12/1/2013,2013,1,Phase 3,1,y,y,,O,"Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures",UCB Pharma,1,Lacosamide,18 years and older,n,nil,>/75,France,2,"North America
Oceania
Europe",n
159,NCT01484977,Baulac 2016,46,74,120,12/1/2013,2013,1,Phase 3,1,y,y,,O,"Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures",UCB Pharma,1,Lacosamide,18 years and older,n,nil,>/75,Germany,2,"North America
Oceania
Europe",n
159,NCT01484977,Baulac 2016,46,74,120,12/1/2013,2013,1,Phase 3,1,y,y,,O,"Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures",UCB Pharma,1,Lacosamide,18 years and older,n,nil,>/75,Romania,2,"North America
Oceania
Europe",n
159,NCT01484977,Baulac 2016,46,74,120,12/1/2013,2013,1,Phase 3,1,y,y,,O,"Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures",UCB Pharma,1,Lacosamide,18 years and older,n,nil,>/75,Spain,2,"North America
Oceania
Europe",n
159,NCT01484977,Baulac 2016,46,74,120,12/1/2013,2013,1,Phase 3,1,y,y,,O,"Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures",UCB Pharma,1,Lacosamide,18 years and older,n,nil,>/75,Sweden,2,"North America
Oceania
Europe",n
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,United States of America,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Argentina,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Australia,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Belgium,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Canada,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Chile,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Germany,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Greece,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Hungary,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,India,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Israel,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,New Zealand,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Poland,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Russian Federation,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,South Africa,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
160,NCT01142193,Chung2014,132,117,249,1/1/2013,2013,1,Phase 3,2,y,y,"2 publication, 1 with subgroup analysis, in view of duplicate population, nly the original study data is extracted",R,"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures",Upsher-Smith Laboratories,1,USL255 | Placebo,18-75,n,75,>/75,Spain,2,"North America
South America
Oceania
Europe
Asia
Africa",Y
161,NCT01375374,elger 2016,10,0,10,3/1/2013,2013,1,Phase 3,1,y,n,,O,"Multicenter, Open-label, Single-arm Study to Evaluate Hormone and Lipid Levels in Male Subjects With Partial-onset Seizures After a Switch of Treatment From Carbamazepine as Adjunctive Treatment to Levetiracetam to Lacosamide as Adjunctive Treatment to Levetiracetam",UCB Pharma,1,Lacosamide | Levetiracetam,18-45,n,45,19-54,Austria,3,Europe,n
161,NCT01375374,elger 2016,10,0,10,3/1/2013,2013,1,Phase 3,1,y,n,,O,"Multicenter, Open-label, Single-arm Study to Evaluate Hormone and Lipid Levels in Male Subjects With Partial-onset Seizures After a Switch of Treatment From Carbamazepine as Adjunctive Treatment to Levetiracetam to Lacosamide as Adjunctive Treatment to Levetiracetam",UCB Pharma,1,Lacosamide | Levetiracetam,18-45,n,45,19-54,Germany,3,Europe,n
161,NCT01375374,elger 2016,10,0,10,3/1/2013,2013,1,Phase 3,1,y,n,,O,"Multicenter, Open-label, Single-arm Study to Evaluate Hormone and Lipid Levels in Male Subjects With Partial-onset Seizures After a Switch of Treatment From Carbamazepine as Adjunctive Treatment to Levetiracetam to Lacosamide as Adjunctive Treatment to Levetiracetam",UCB Pharma,1,Lacosamide | Levetiracetam,18-45,n,45,19-54,Spain,3,Europe,n
162,NCT00537940,French 2016,257,225,482,7/1/2013,2013,2,Phase 4,1,y,y,,R,"A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.",Pfizer,1,Pregabalin | Gabapentin,18-80,n,80,>/75,Costa Rica,3,"North America
South America",N
162,NCT00537940,French 2016,257,225,482,7/1/2013,2013,2,Phase 4,1,y,y,,R,"A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.",Pfizer,1,Pregabalin | Gabapentin,18-80,n,80,>/75,El Salvador,3,"North America
South America",N
162,NCT00537940,French 2016,257,225,482,7/1/2013,2013,2,Phase 4,1,y,y,,R,"A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.",Pfizer,1,Pregabalin | Gabapentin,18-80,n,80,>/75,Guatemala,3,"North America
South America",N
162,NCT00537940,French 2016,257,225,482,7/1/2013,2013,2,Phase 4,1,y,y,,R,"A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.",Pfizer,1,Pregabalin | Gabapentin,18-80,n,80,>/75,Peru,3,"North America
South America",N
162,NCT00537940,French 2016,257,225,482,7/1/2013,2013,2,Phase 4,1,y,y,,R,"A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.",Pfizer,1,Pregabalin | Gabapentin,18-80,n,80,>/75,,3,"North America
South America",N
163,NCT01434225,Pressler 2015,10,4,14,6/1/2013,2013,1,Phase 1/Phase 2,1,y,n,,O,NEMO1: An Open Label Exploratory Dose Finding and Pharmacokinetic Clinical Trial of Bumetanide for the Treatment of Neonatal Seizure Using Medication Off-patent,Great Ormond Street Hospital for Children NHS Foundation Trust,2,Bumetanide,up to 48 hours,y,0.005,</18,Ireland,3,Europe,n
163,NCT01434225,Pressler 2015,10,4,14,6/1/2013,2013,1,Phase 1/Phase 2,1,y,n,,O,NEMO1: An Open Label Exploratory Dose Finding and Pharmacokinetic Clinical Trial of Bumetanide for the Treatment of Neonatal Seizure Using Medication Off-patent,Great Ormond Street Hospital for Children NHS Foundation Trust,2,Bumetanide,up to 48 hours,y,0.005,</18,Netherlands,3,Europe,n
163,NCT01434225,Pressler 2015,10,4,14,6/1/2013,2013,1,Phase 1/Phase 2,1,y,n,,O,NEMO1: An Open Label Exploratory Dose Finding and Pharmacokinetic Clinical Trial of Bumetanide for the Treatment of Neonatal Seizure Using Medication Off-patent,Great Ormond Street Hospital for Children NHS Foundation Trust,2,Bumetanide,up to 48 hours,y,0.005,</18,Sweden,3,Europe,n
163,NCT01434225,Pressler 2015,10,4,14,6/1/2013,2013,1,Phase 1/Phase 2,1,y,n,,O,NEMO1: An Open Label Exploratory Dose Finding and Pharmacokinetic Clinical Trial of Bumetanide for the Treatment of Neonatal Seizure Using Medication Off-patent,Great Ormond Street Hospital for Children NHS Foundation Trust,2,Bumetanide,up to 48 hours,y,0.005,</18,United Kingdom of Great Britain and Northern Ireland,3,Europe,n
164,NCT00629889,rosetti 2014,31,21,52,5/1/2013,2013,1,Phase 2,1,y,n,,O,Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study.,Centre Hospitalier Universitaire Vaudois,2,levetiracetam | pregabalin,18 years and older,n,nil,>/75,Switzerland,3,Europe,n
165,NCT00866775,Sperling 2015,92,101,192,5/1/2013,2013,1,Phase 3,1,y,y,,R,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs",Sunovion,1,Eslicarbazepine acetate | Eslicarbazepine acetate,16-70,y,70,65-<75,United States of America,2,North America,N
165,NCT00866775,Sperling 2015,92,101,192,5/1/2013,2013,1,Phase 3,1,y,y,,R,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs",Sunovion,1,Eslicarbazepine acetate | Eslicarbazepine acetate,16-70,y,70,65-<75,Canada,2,North America,N
166,NCT01653262,Yates 2015,14,15,29,11/1/2013,2013,1,Phase 3,1,y,y,,O,"An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,United States of America,2,"North America
Europe",n
166,NCT01653262,Yates 2015,14,15,29,11/1/2013,2013,1,Phase 3,1,y,y,,O,"An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,France,2,"North America
Europe",n
166,NCT01653262,Yates 2015,14,15,29,11/1/2013,2013,1,Phase 3,1,y,y,,O,"An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,Germany,2,"North America
Europe",n
166,NCT01653262,Yates 2015,14,15,29,11/1/2013,2013,1,Phase 3,1,y,y,,O,"An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,Spain,2,"North America
Europe",n
166,NCT01653262,Yates 2015,14,15,29,11/1/2013,2013,1,Phase 3,1,y,y,,O,"An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,United Kingdom of Great Britain and Northern Ireland,2,"North America
Europe",n
167,NCT00319501,2016,118,116,234,7/1/2014,2014,2,Phase 3,0,n,y,,R,"A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures",Pfizer,1,Placebo | Vanquix Auto-Injector (Diazepam Injection),2 years and older,y,nil,>/75,United States of America,2,"North America
Europe",N
167,NCT00319501,2016,118,116,234,7/1/2014,2014,2,Phase 3,0,n,y,,R,"A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures",Pfizer,1,Placebo | Vanquix Auto-Injector (Diazepam Injection),2 years and older,y,nil,>/75,Bulgaria,2,"North America
Europe",N
167,NCT00319501,2016,118,116,234,7/1/2014,2014,2,Phase 3,0,n,y,,R,"A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures",Pfizer,1,Placebo | Vanquix Auto-Injector (Diazepam Injection),2 years and older,y,nil,>/75,czechiaia,2,"North America
Europe",N
167,NCT00319501,2016,118,116,234,7/1/2014,2014,2,Phase 3,0,n,y,,R,"A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures",Pfizer,1,Placebo | Vanquix Auto-Injector (Diazepam Injection),2 years and older,y,nil,>/75,Serbia,2,"North America
Europe",N
167,NCT00319501,2016,118,116,234,7/1/2014,2014,2,Phase 3,0,n,y,,R,"A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures",Pfizer,1,Placebo | Vanquix Auto-Injector (Diazepam Injection),2 years and older,y,nil,>/75,Ukraine,2,"North America
Europe",N
167,NCT00319501,2016,118,116,234,7/1/2014,2014,2,Phase 3,0,n,y,,R,"A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures",Pfizer,1,Placebo | Vanquix Auto-Injector (Diazepam Injection),2 years and older,y,nil,>/75,,2,"North America
Europe",N
168,NCT01089504,2016,6,7,13,11/1/2014,2014,2,Phase 4,0,n,y,,R,Prophylactic Phenobarbital After Resolution of Neonatal Seizures,University of Rochester,2,phenobarbital | placebo,up to 2 weeks,y,0.04,</18,United States of America,1,North America,N
169,NCT01190098,2016,16,36,52,11/1/2014,2014,2,Phase 4,0,n,y,,R,"Searching for ""Sleep Friendly"" Therapies for a Sleepy Population: A Double-Blind, Placebo-Controlled, Randomized Trial to Assess the Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy",The Cleveland Clinic,2,Lacosamide | Placebo,18 years and older,n,nil,>/75,United States of America,1,North America,N
170,NCT01431963,2016,39,26,65,10/1/2014,2014,2,Phase 3,0,n,y,,O,"A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy in Newly Diagnosed Epilepsy or Recurrent Epilepsy (Currently Untreated)",GlaxoSmithKline,1,Lamictal,16 years and older,y,nil,>/75,Japan,4,Asia,n
170,NCT01431963,2016,39,26,65,10/1/2014,2014,2,Phase 3,0,n,y,,O,"A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy in Newly Diagnosed Epilepsy or Recurrent Epilepsy (Currently Untreated)",GlaxoSmithKline,1,Lamictal,16 years and older,y,nil,>/75,"Korea, Republic of",4,Asia,n
171,NCT01710657,2017,300,247,547,8/1/2014,2014,2,Phase 3,0,n,y,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization",UCB Pharma,1,Lacosamide 50 mg | Lacosamide 100 mg | Placebo,16-70,y,70,65-<75,China,4,Asia,N
171,NCT01710657,2017,300,247,547,8/1/2014,2014,2,Phase 3,0,n,y,,R,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization",UCB Pharma,1,Lacosamide 50 mg | Lacosamide 100 mg | Placebo,16-70,y,70,65-<75,Japan,4,Asia,N
172,NCT01289912,2018,24,23,47,12/1/2014,2014,2,Phase 2,0,n,y,,R,Randomized Double-Blind Phase 2 Trial Of RAD001 For Neurocognition In Individuals With Tuberous Sclerosis Complex,Boston Children_ã_s Hospital,2,RAD001 | Placebo,6_21,y,21,19-54,United States of America,1,North America,N
173,NCT02088957,2018,0,1,1,10/1/2014,2014,2,Phase 2,0,n,y,,O,"A Randomized, Open-label, Multicenter, Parallel-group, Exploratory Study to Evaluate the Efficacy of Intravenous Brivaracetam and Intravenous Phenytoin in Subjects Experiencing Nonconvulsive Electrographic Seizures",UCB Pharma,1,Brivaracetam intravenous solution | Brivaracetam oral tablets | Phenytoin intravenous solution | Phenytoin oral tablets,16 years and older,y,nil,>/75,United States of America,1,North America,n
174,NCT00938431,2019,23,24,47,8/1/2014,2014,2,Phase 2,1,y,y,publication does not report demographic,O,"A Multicenter, Open-Label Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Lacosamide (LCM) Oral Solution (Syrup) As Adjunctive Therapy In Children With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,1 month to 17 years,y,17,</18,United States of America,2,"North America
Europe",n
174,NCT00938431,2019,23,24,47,8/1/2014,2014,2,Phase 2,1,y,y,publication does not report demographic,O,"A Multicenter, Open-Label Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Lacosamide (LCM) Oral Solution (Syrup) As Adjunctive Therapy In Children With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,1 month to 17 years,y,17,</18,Belgium,2,"North America
Europe",n
174,NCT00938431,2019,23,24,47,8/1/2014,2014,2,Phase 2,1,y,y,publication does not report demographic,O,"A Multicenter, Open-Label Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Lacosamide (LCM) Oral Solution (Syrup) As Adjunctive Therapy In Children With Partial-Onset Seizures",UCB Pharma,1,Lacosamide,1 month to 17 years,y,17,</18,Mexico,2,"North America
Europe",n
175,NCT01806805,Hainque 2016,11,12,23,7/1/2014,2014,2,Phase 3,1,y,n,,R,"Comparative Study of the Efficiency of Zonisamide in Myoclonus Dystonia: A Monocentric , Randomized in Cross Over and Double Blind Study Versus Placebo Study",Assistance Publique - Hêäpitaux de Paris,2,zonegran | placebo,18-60,n,60,55-<65,France,3,Europe,N
176,NCT01498822,Kim 2017,159,186,347,7/1/2014,2014,2,Phase 4,1,y,y,,O,"A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Partial Epilepsy",UCB Pharma,1,Levetiracetam | Oxcarbazepine,16-80,y,80,>/75,"Korea, Republic of",4,Asia,n
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,United States of America,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Austria,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Belgium,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Brazil,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Bulgaria,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Canada,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,czechiaia,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Estonia,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Finland,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,France,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Germany,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Hong Kong,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Hungary,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,India,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Italy,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Japan,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,"Korea, Republic of",2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Latvia,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Lithuania,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Mexico,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Netherlands,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Poland,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Puerto Rico,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Russian Federation,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Spain,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,Sweden,2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,"Taiwan, Province of China",2,"North America
Europe
Asia
South America",N
177,NCT01261325,Klein 2015,368,396,764,5/1/2014,2014,2,Phase 3,10,y,y,"10 publication, only study which is unique to clinic trial ID recorded as others include pooled data, result showed both ITT and safety ,safety data is included",R,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (__‰16 to 80 Years Old) With Partial Onset Seizures",UCB Pharma,1,Placebo | Brivaracetam | Brivaracetam | Antiepileptic drugs with market authorization available per country,16-80,y,80,>/75,United Kingdom of Great Britain and Northern Ireland,2,"North America
Europe
Asia
South America",N
178,NCT01345058,lee 2016,26,30,56,10/21/2014,2014,2,Phase 3,1,y,y,,O,Open Label Trial of Add on Lacosamide Versus High Dose Monotherapy in Patients With a Seizure Disorder,Brigham and Women's Hospital,2,lacosamide | levetiracetam,18 years and older,n,nil,>/75,United States of America,1,North America,n
179,NCT01161524,meador 2016,80,53,133,9/1/2014,2014,2,Phase 2,2,y,n,"2 publication, 1 with RCT 1 with OL,RCT data used",R,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics When Administered as an Adjunctive Therapy in Adolescents (12 to Less Than 18 Years of Age) With Inadequately Controlled Partial-onset Seizures",Eisai Inc.,1,Perampanel | Placebo,12–18,y,18,</18,United States of America,1,North America,y
180,NCT01228747,wu 2018,155,96,251,5/1/2014,2014,2,Phase 3,1,y,y,,R,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Oral Levetiracetam, in Epilepsy Patients Aged __‰16 Years, With Generalized Tonic-clonic (GTC) Seizures",UCB Pharma,1,Levetiracetam | Placebo,16 years and older,y,nil,>/75,Japan,4,Asia,y
180,NCT01228747,wu 2018,155,96,251,5/1/2014,2014,2,Phase 3,1,y,y,,R,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Oral Levetiracetam, in Epilepsy Patients Aged __‰16 Years, With Generalized Tonic-clonic (GTC) Seizures",UCB Pharma,1,Levetiracetam | Placebo,16 years and older,y,nil,>/75,China,4,Asia,y
181,NCT02332174,Xu 2015,20,20,40,6/1/2014,2014,2,Phase 1,1,y,n,,O,Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects,"Wuhan Union Hospital, China",2,rufinamide,18-40,n,40,19-54,China,4,Asia,n
182,NCT01506882,2015,33,38,71,4/1/2015,2015,2,Phase 3,0,n,y,,O,"An Open-label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Levetiracetam Used as Monotherapy in Newly or Recently Diagnosed Epilepsy Patients Aged Older Than or Equal to 16 Years With Partial Seizures",UCB Pharma,1,Levetiracetam (LEV),16 years and older,y,nil,>/75,Japan,4,Asia,n
183,NCT01527006,2016,34,16,50,4/1/2015,2015,2,Phase 2,0,n,y,,O,"An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Pediatric Subjects From 2 to Less Than 12 Years of Age With Epilepsy",Eisai Inc.,1,perampanel,2_11,y,11,</18,United States of America,1,North America,n
184,NCT01982812,2016,20,24,44,6/1/2015,2015,2,Phase 2,0,n,y,,O,A Safety and Feasibility Study of Enteral Levetiracetam vs. Phenobarbital for Seizure Control in Pediatric Cerebral Malaria,University of Rochester,2,Oral Levetiracetam | Standard AED,24-83 months,y,6.9,</18,Malawi,3,Africa,n
185,NCT01229735,2017,208,135,343,5/1/2015,2015,2,Phase 4,0,n,y,,O,"A Randomized, Open-label, Parallel Group, Multi-center, Comparative, Phase IV Trial of Levetiracetam (LEV) Versus Topiramate (TPM) as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures",UCB Pharma,1,Levetiracetam | Topiramate,16–80,y,80,>/75,"Korea, Republic of",4,Asia,n
186,NCT01431976,2017,7,13,20,11/1/2015,2015,2,Phase 3,0,n,y,,O,"A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy on Newly Diagnosed Typical Absence Seizures in Children and Adolescents",GlaxoSmithKline,1,Lamictal,2_15,y,15,</18,Japan,4,Asia,n
186,NCT01431976,2017,7,13,20,11/1/2015,2015,2,Phase 3,0,n,y,,O,"A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy on Newly Diagnosed Typical Absence Seizures in Children and Adolescents",GlaxoSmithKline,1,Lamictal,2_15,y,15,</18,"Korea, Republic of",4,Asia,n
187,NCT01954121,2017,233,200,433,9/1/2015,2015,2,Phase 3,0,n,y,,O,"An Open-label, Randomized, Parallel-group, Active-controlled Study Comparing the Efficacy and Safety of Levetiracetam to Carbamazepine Used as Monotherapy in Subjects Newly or Recently Diagnosed as Epilepsy and Partial-onset Seizures",UCB Pharma,1,Levetiracetam | Carbamazepine,16 years and older,y,nil,>/75,China,4,Asia,n
188,NCT02100644,2017,0,33,33,5/11/2015,2015,2,Phase 4,0,n,y,,O,"Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study -",GlaxoSmithKline,1,Lamotrigine tablets 25/100 mg,15 years and older,y,nil,>/75,Japan,4,Asia,n
189,NCT02187809,2017,0,1,1,10/1/2015,2015,2,Phase 3,0,n,y,,O,"Multi-site, Prospective, Open-label, Long-term, Flexible Dose, Interventional Study to Evaluate the Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged __‰1 to ___16 Years With Dravet Syndrome",H. Lundbeck A/S,1,Clobazam,1–16,y,16,</18,United States of America,2,North America,n
189,NCT02187809,2017,0,1,1,10/1/2015,2015,2,Phase 3,0,n,y,,O,"Multi-site, Prospective, Open-label, Long-term, Flexible Dose, Interventional Study to Evaluate the Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged __‰1 to ___16 Years With Dravet Syndrome",H. Lundbeck A/S,1,Clobazam,1–16,y,16,</18,Mexico,2,North America,n
189,NCT02187809,2017,0,1,1,10/1/2015,2015,2,Phase 3,0,n,y,,O,"Multi-site, Prospective, Open-label, Long-term, Flexible Dose, Interventional Study to Evaluate the Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged __‰1 to ___16 Years With Dravet Syndrome",H. Lundbeck A/S,1,Clobazam,1–16,y,16,</18,,2,North America,n
189,NCT02187809,2017,0,1,1,10/1/2015,2015,2,Phase 3,0,n,y,,O,"Multi-site, Prospective, Open-label, Long-term, Flexible Dose, Interventional Study to Evaluate the Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged __‰1 to ___16 Years With Dravet Syndrome",H. Lundbeck A/S,1,Clobazam,1–16,y,16,</18,,2,North America,n
190,NCT01278173,2018,37,28,65,5/1/2015,2015,2,Phase 4,0,n,y,,O,"A Prospective, Open-label Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (SabrilÔÎ)",Lundbeck LLC,1,Sabril,18 years and older,n,nil,>/75,United States of America,1,North America,n
191,NCT01999777,2018,23,39,62,8/1/2015,2015,2,Phase 3,0,n,y,,R,"A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)","Proximagen, LLC",1,USL261 | Placebo,12 years and older,y,nil,>/75,United States of America,2,"North America
Oceania
Europe",N
191,NCT01999777,2018,23,39,62,8/1/2015,2015,2,Phase 3,0,n,y,,R,"A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)","Proximagen, LLC",1,USL261 | Placebo,12 years and older,y,nil,>/75,Australia,2,"North America
Oceania
Europe",N
191,NCT01999777,2018,23,39,62,8/1/2015,2015,2,Phase 3,0,n,y,,R,"A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)","Proximagen, LLC",1,USL261 | Placebo,12 years and older,y,nil,>/75,Austria,2,"North America
Oceania
Europe",N
191,NCT01999777,2018,23,39,62,8/1/2015,2015,2,Phase 3,0,n,y,,R,"A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)","Proximagen, LLC",1,USL261 | Placebo,12 years and older,y,nil,>/75,Belgium,2,"North America
Oceania
Europe",N
191,NCT01999777,2018,23,39,62,8/1/2015,2015,2,Phase 3,0,n,y,,R,"A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)","Proximagen, LLC",1,USL261 | Placebo,12 years and older,y,nil,>/75,czechiaia,2,"North America
Oceania
Europe",N
191,NCT01999777,2018,23,39,62,8/1/2015,2015,2,Phase 3,0,n,y,,R,"A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)","Proximagen, LLC",1,USL261 | Placebo,12 years and older,y,nil,>/75,Germany,2,"North America
Oceania
Europe",N
191,NCT01999777,2018,23,39,62,8/1/2015,2015,2,Phase 3,0,n,y,,R,"A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)","Proximagen, LLC",1,USL261 | Placebo,12 years and older,y,nil,>/75,Lithuania,2,"North America
Oceania
Europe",N
191,NCT01999777,2018,23,39,62,8/1/2015,2015,2,Phase 3,0,n,y,,R,"A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)","Proximagen, LLC",1,USL261 | Placebo,12 years and older,y,nil,>/75,Spain,2,"North America
Oceania
Europe",N
192,NCT02161185,2019,4,3,7,5/1/2015,2015,2,Phase 3,0,n,y,,O,An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters,"Proximagen, LLC",1,USL261,12–65,y,65,65-<75,United States of America,1,North America,n
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,United States of America,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Australia,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Belgium,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Bulgaria,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Canada,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,czechiaia,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Finland,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,France,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Germany,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Greece,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Hungary,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Italy,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Japan,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,"Korea, Republic of",2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Latvia,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Lithuania,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Mexico,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Philippines,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Poland,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Portugal,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Romania,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Russian Federation,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Slovakia,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Spain,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Sweden,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Switzerland,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Thailand,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,Ukraine,2,"North America
Oceania
Europe
Asia
",N
193,NCT01243177,Baulac 2016,475,411,886,8/1/2015,2015,2,Phase 3,2,y,y,"2 publication, 1 with separate analysis, in view of duplicate population, nly the original study data is extracted",R,"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (__‰ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.",UCB Pharma,1,Lacosamide | Carbamazepine-Controlled Release,16 years and older,y,nil,>/75,United Kingdom of Great Britain and Northern Ireland,2,"North America
Oceania
Europe
Asia
",N
194,NCT01458522,Belcastro 2013,7,9,16,7/1/2015,2015,2,Phase 2,1,y,y,,O,Utility of Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures,Duke University,2,fPHT | LCM,18 years and older,n,nil,>/75,United States of America,1,North America,n
195,NCT02091375,Devinsky 2017,62,58,120,11/26/2015,2015,2,Phase 3,1,y,y,,R,"A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome",GW Research Ltd,2,GWP42003-P 20 mg/kg/day Dose | Placebo control,2_18,y,18,</18,United States of America,2,"North America
Europe",Y
195,NCT02091375,Devinsky 2017,62,58,120,11/26/2015,2015,2,Phase 3,1,y,y,,R,"A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome",GW Research Ltd,2,GWP42003-P 20 mg/kg/day Dose | Placebo control,2_18,y,18,</18,France,2,"North America
Europe",Y
195,NCT02091375,Devinsky 2017,62,58,120,11/26/2015,2015,2,Phase 3,1,y,y,,R,"A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome",GW Research Ltd,2,GWP42003-P 20 mg/kg/day Dose | Placebo control,2_18,y,18,</18,Poland,2,"North America
Europe",Y
195,NCT02091375,Devinsky 2017,62,58,120,11/26/2015,2015,2,Phase 3,1,y,y,,R,"A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome",GW Research Ltd,2,GWP42003-P 20 mg/kg/day Dose | Placebo control,2_18,y,18,</18,United Kingdom of Great Britain and Northern Ireland,2,"North America
Europe",Y
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,Australia,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,Austria,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,China,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,czechiaia,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,France,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,Germany,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,Greece,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,India,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,Israel,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,Japan,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,Latvia,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,Lithuania,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,Poland,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,Serbia,2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,"Korea, Republic of",2,"Oceania
Europe
Asia
North America",N
196,NCT01393743,French 2015,71,91,162,11/1/2015,2015,2,Phase 3,1,y,1,,R,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures",Eisai Inc.,1,Perampanel | Placebo comparator,12 years and older,y,nil,>/75,United States of America,2,"Oceania
Europe
Asia
North America",N
197,NCT01175954,Lancman 2016,13,21,34,12/1/2015,2015,2,Phase 4,1,y,n,,O,Phase IV Study of Cognitive and Behavioral Effects of Lacosamide as Adjunctive Therapy in Patients With Partial Epilepsy,Northeast Regional Epilepsy Group,2,Lacosamide | Lacosamide,18–70,n,70,65-<75,United States of America,1,North America,n
198,NCT01713777,privitera 2016,11,22,33,9/1/2015,2015,2,Phase 4,1,y,n,,R,Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design (EQUIGEN Chronic-Dose Study),University of Cincinnati,2,"Lamotrigine Generic ""A"" | Lamotrigine generic ""B""",18 years and older,n,nil,>/75,United States of America,1,North America,N
199,NCT01974700,2016,2,6,8,2/1/2016,2016,2,Phase 4,0,n,y,,O,Seizure Prophylaxis in Aneurysm Repair,Indiaa University,2,Levetiracetam,18 years and older,n,nil,>/75,United States of America,1,North America,n
200,NCT01398956,2017,28,16,44,4/1/2016,2016,2,Phase 3,0,n,y,,O,"An Open-label, Multicenter, Long-term, Follow-up Study in Japan to Evaluate the Safety, Tolerability, and Efficacy of Adjunctive Treatment With Oral L059 (Levetiracetam) in Epilepsy Subjects With Generalized Tonic-clonic (GTC) Seizures",UCB Pharma,1,Levetiracetam,4 years and older,y,nil,>/75,Japan,4,Asia,n
201,NCT02324673,2017,33,28,61,5/9/2016,2016,2,Phase 1/Phase 2,0,n,y,,O,A Phase 1/2 Study to Assess the Pharmacokinetics and Safety of Multiple Doses of Pharmaceutical Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Seizure Disorders,INSYS Therapeutics Inc,1,Cannabidiol Oral Solution,1-17 years,y,17,</18,United States of America,1,North America,n
202,NCT01607346,2018,6,4,10,11/16/2016,2016,2,Phase 4,0,n,y,,O,An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures,GlaxoSmithKline,1,ezogabine/retigabine,18 years and older,n,nil,>/75,United States of America,2,"North America
Europe",n
202,NCT01607346,2018,6,4,10,11/16/2016,2016,2,Phase 4,0,n,y,,O,An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures,GlaxoSmithKline,1,ezogabine/retigabine,18 years and older,n,nil,>/75,France,2,"North America
Europe",n
202,NCT01607346,2018,6,4,10,11/16/2016,2016,2,Phase 4,0,n,y,,O,An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures,GlaxoSmithKline,1,ezogabine/retigabine,18 years and older,n,nil,>/75,Poland,2,"North America
Europe",n
203,NCT02316847,2018,57,51,108,9/1/2016,2016,2,Phase 2,0,n,y,,O,"Multi-center, Open-label, Study of Safety and Tolerability of Chronic Intermittent United States of Americage of Diazepam Nasal Spray in Adolescents and Adult Patients With Cluster Seizures, Including Assessment of Olfaction and Reported Changes in Taste.",Acorda Therapeutics,1,diazepam nasal spray,12–65,y,65,65-<75,United States of America,1,North America,n
204,NCT02474407,2018,27,51,78,7/1/2016,2016,2,Phase 2,0,n,y,,O,"An Open-Label, Randomized, Crossover Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (DiastatÔÎ) in Patients With Refractory Epilepsy",Acorda Therapeutics,1,diazepam nasal spray | diazepam rectal gel,12–65,y,65,65-<75,United States of America,1,North America,n
205,NCT02551731,2018,3,6,9,9/6/2016,2016,2,Phase 2,0,n,y,,O,A Phase 2 Study to Assess the Efficacy and Safety of Cannabidiol Oral Solution for the Treatment of Refractory Infantile Spasms,INSYS Therapeutics Inc,1,Cannabidiol Oral Solution,6 months to 36 months,y,36,19-54,United States of America,1,North America,n
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,United States of America,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Belgium,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Bulgaria,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,czechiaia,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,France,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Greece,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Hungary,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Israel,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Italy,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,"Korea, Republic of",2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Malaysia,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Philippines,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Poland,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Romania,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Serbia,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Singapore,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Turkey,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,Ukraine,2,"North America
Europe
Asia",N
206,NCT01389596,Antinew 2018,162,133,295,8/1/2016,2016,2,Phase 3,1,y,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin add-on therapy | Pregabalin add-on therapy | Pregabalin add-on therapy,4_16,y,16,</18,,2,"North America
Europe
Asia",N
207,NCT00088452,Glauser 2010,193,278,471,8/31/2016,2016,1,Phase 3,4,y,n,"4 publications,all comprise same population, original study is recorded",R,Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study,"Children's Hospital Medical Center, Cincinnati",2,ethosuximide | lamotrigine | valproic acid,13 months - 13 years,y,13,</18,United States of America,1,North America,N
208,NCT01724918,Huang 2018,30,41,71,8/1/2016,2016,2,Phase 2,1,y,n,,R,Lacosamide IV and EEG/EKG (LIVE) Study,Lawson Health Research Institute,2,Lacosamide,18-65,n,65,65-<75,Canada,3,North America,N
209,NCT02224690,Thiele 2018,88,83,171,3/18/2016,2016,2,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.",GW Research Ltd,2,GWP42003-P 20 mg/kg/day Dose | Placebo,2_55,y,55,55-<65,United States of America,2,"North America
Europe",Y
209,NCT02224690,Thiele 2018,88,83,171,3/18/2016,2016,2,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.",GW Research Ltd,2,GWP42003-P 20 mg/kg/day Dose | Placebo,2_55,y,55,55-<65,Netherlands,2,"North America
Europe",Y
209,NCT02224690,Thiele 2018,88,83,171,3/18/2016,2016,2,Phase 3,1,y,y,,R,"A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.",GW Research Ltd,2,GWP42003-P 20 mg/kg/day Dose | Placebo,2_55,y,55,55-<65,Poland,2,"North America
Europe",Y
210,NCT01162460,Trinka 2017,448,365,813,9/1/2016,2016,2,Phase 3,1,y,n,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures:a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study",Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093),18 years and older,n,nil,>/75,Portugal,3,Europe,Y
211,NCT00761774,2018,52,56,108,3/1/2017,2017,2,Phase 3,0,n,y,,O,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,United States of America,2,"North America
Oceania
Europe
",n
211,NCT00761774,2018,52,56,108,3/1/2017,2017,2,Phase 3,0,n,y,,O,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,Australia,2,"North America
Oceania
Europe
",n
211,NCT00761774,2018,52,56,108,3/1/2017,2017,2,Phase 3,0,n,y,,O,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,Belgium,2,"North America
Oceania
Europe
",n
211,NCT00761774,2018,52,56,108,3/1/2017,2017,2,Phase 3,0,n,y,,O,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,Canada,2,"North America
Oceania
Europe
",n
211,NCT00761774,2018,52,56,108,3/1/2017,2017,2,Phase 3,0,n,y,,O,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,czechiaia,2,"North America
Oceania
Europe
",n
211,NCT00761774,2018,52,56,108,3/1/2017,2017,2,Phase 3,0,n,y,,O,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,France,2,"North America
Oceania
Europe
",n
211,NCT00761774,2018,52,56,108,3/1/2017,2017,2,Phase 3,0,n,y,,O,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,Germany,2,"North America
Oceania
Europe
",n
211,NCT00761774,2018,52,56,108,3/1/2017,2017,2,Phase 3,0,n,y,,O,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,Hungary,2,"North America
Oceania
Europe
",n
211,NCT00761774,2018,52,56,108,3/1/2017,2017,2,Phase 3,0,n,y,,O,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,Italy,2,"North America
Oceania
Europe
",n
211,NCT00761774,2018,52,56,108,3/1/2017,2017,2,Phase 3,0,n,y,,O,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,Spain,2,"North America
Oceania
Europe
",n
211,NCT00761774,2018,52,56,108,3/1/2017,2017,2,Phase 3,0,n,y,,O,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.",UCB Pharma,1,Brivaracetam,16 years and older,y,nil,>/75,Sweden,2,"North America
Oceania
Europe
",n
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Austria,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Bosnia and Herzegovina,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Croatia,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,czechiaia,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,France,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Germany,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Hungary,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Italy,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Malaysia,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,"Moldova, Korea, Republic of",3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Philippines,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Poland,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Portugal,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Romania,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Russian Federation,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Serbia,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Slovakia,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Spain,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,"Taiwan, Province of China",3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,Ukraine,3,"Europe
Asia
",N
212,NCT00988156,2018,126,137,263,8/24/2017,2017,2,Phase 3,0,n,y,,R,Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children,Bial - Portela C S.A.,1,Eslicarbazepine acetate (BIA 2-093) | Eslicarbazepine acetate,2_16,y,16,</18,United Kingdom of Great Britain and Northern Ireland,3,"Europe
Asia
",N
213,NCT01281956,2018,7,3,10,10/5/2017,2017,2,Phase 2,0,n,y,,R,A Phase II Clinical Trial of PRX-00023 Therapy in Localization-Related Epilepsy,National Institutes of Health Clinical Center (CC),2,PRX-00023,18-65,n,65,65-<75,United States of America,1,North America,N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,United States of America,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Argentina,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Australia,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Belgium,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Bulgaria,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Colombia,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Croatia,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,czechiaia,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Estonia,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Georgia,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Hungary,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Israel,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Italy,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,"Korea, Republic of",2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Latvia,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Lithuania,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Mexico,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Montenegro,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Poland,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Romania,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Russian Federation,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Serbia,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Slovakia,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Slovenia,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,"Taiwan, Province of China",2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Thailand,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,Ukraine,2,"North America
Oceania
Europe
Asia
",N
214,NCT01921205,2018,190,153,343,1/24/2017,2017,2,Phase 3,0,n,y,,R,"A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy __‰4 Years to <17 Years of Age With Partial Onset Seizures",UCB Pharma,1,Lacosamide | Placebo,4_16,y,16,</18,United Kingdom of Great Britain and Northern Ireland,2,"North America
Oceania
Europe
Asia
",N
215,NCT02363933,2018,6,2,8,4/10/2017,2017,2,Phase 4,0,n,y,,O,Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors,Duke University,2,Perampanel,18 years and older,n,nil,>/75,United States of America,1,North America,n
216,NCT02495844,2019,26,29,55,7/1/2017,2017,2,Phase 2,0,n,y,,R,"Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.","UCB Pharma
",1,UCB0942 | UCB0942 | Placebo,18 years and older,n,nil,>/75,Belgium,3,Europe,N
216,NCT02495844,2019,26,29,55,7/1/2017,2017,2,Phase 2,0,n,y,,R,"Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.","UCB Pharma
",1,UCB0942 | UCB0942 | Placebo,18 years and older,n,nil,>/75,Bulgaria,3,Europe,N
216,NCT02495844,2019,26,29,55,7/1/2017,2017,2,Phase 2,0,n,y,,R,"Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.","UCB Pharma
",1,UCB0942 | UCB0942 | Placebo,18 years and older,n,nil,>/75,Germany,3,Europe,N
216,NCT02495844,2019,26,29,55,7/1/2017,2017,2,Phase 2,0,n,y,,R,"Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.","UCB Pharma
",1,UCB0942 | UCB0942 | Placebo,18 years and older,n,nil,>/75,Hungary,3,Europe,N
216,NCT02495844,2019,26,29,55,7/1/2017,2017,2,Phase 2,0,n,y,,R,"Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.","UCB Pharma
",1,UCB0942 | UCB0942 | Placebo,18 years and older,n,nil,>/75,Netherlands,3,Europe,N
216,NCT02495844,2019,26,29,55,7/1/2017,2017,2,Phase 2,0,n,y,,R,"Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.","UCB Pharma
",1,UCB0942 | UCB0942 | Placebo,18 years and older,n,nil,>/75,Spain,3,Europe,N
216,NCT02495844,2019,26,29,55,7/1/2017,2017,2,Phase 2,0,n,y,,R,"Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.","UCB Pharma
",1,UCB0942 | UCB0942 | Placebo,18 years and older,n,nil,>/75,,3,Europe,N
217,NCT02705768,Maiti 2017,44,16,60,3/1/2017,2017,2,Phase 4,1,y,n,,O,Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures,"All India Institute of Medical Sciences, Bhubaneswar",2,Carbamazepine | Oxcarbazepine,18-45,n,45,19-54,India,4,Asia,n
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,United States of America,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Belarus,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Belgium,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Bosnia and Herzegovina,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Bulgaria,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,China,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,France,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Germany,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Greece,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Hungary,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Israel,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,"Korea, Republic of",2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Lebanon,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Malaysia,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Philippines,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Romania,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Russian Federation,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Serbia,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Spain,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,"Taiwan, Province of China",2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Thailand,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Turkey,2,"North America
Europe
Asia
",N
218,NCT02072824,2018,103,72,175,3/13/2018,2018,2,Phase 3,0,n,y,,R,"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures",Pfizer,1,Pregabalin Dose Level 1 | Pregabalin Dose Level 2 | Placebo,1 month to 3 years,y,3,</18,Ukraine,2,"North America
Europe
Asia
",N
219,NCT02655198,Lagae 2018,9,4,13,12/1/2018,2018,2,phase 2,1,y,n,,O,Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy,KU Leuven,2,Fenfluramine,3_18,y,18,</18,Belgium,3,Europe,n
220,NCT00988429,2018,326,324,650,1/1/2019,2019,2,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",Bial - Portela C S.A.,1,800 mg QD Eslicarbazepine acetate | 1200 mg QD Eslicarbazepine acetate | Placebo,16 years and older,y,nil,>/75,United States of America,2,"North America
South America
Europe
",N
220,NCT00988429,2018,326,324,650,1/1/2019,2019,2,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",Bial - Portela C S.A.,1,800 mg QD Eslicarbazepine acetate | 1200 mg QD Eslicarbazepine acetate | Placebo,16 years and older,y,nil,>/75,Argentina,2,"North America
South America
Europe
",N
220,NCT00988429,2018,326,324,650,1/1/2019,2019,2,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",Bial - Portela C S.A.,1,800 mg QD Eslicarbazepine acetate | 1200 mg QD Eslicarbazepine acetate | Placebo,16 years and older,y,nil,>/75,Belgium,2,"North America
South America
Europe
",N
220,NCT00988429,2018,326,324,650,1/1/2019,2019,2,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",Bial - Portela C S.A.,1,800 mg QD Eslicarbazepine acetate | 1200 mg QD Eslicarbazepine acetate | Placebo,16 years and older,y,nil,>/75,Brazil,2,"North America
South America
Europe
",N
220,NCT00988429,2018,326,324,650,1/1/2019,2019,2,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",Bial - Portela C S.A.,1,800 mg QD Eslicarbazepine acetate | 1200 mg QD Eslicarbazepine acetate | Placebo,16 years and older,y,nil,>/75,Canada,2,"North America
South America
Europe
",N
220,NCT00988429,2018,326,324,650,1/1/2019,2019,2,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",Bial - Portela C S.A.,1,800 mg QD Eslicarbazepine acetate | 1200 mg QD Eslicarbazepine acetate | Placebo,16 years and older,y,nil,>/75,Cyprus,2,"North America
South America
Europe
",N
220,NCT00988429,2018,326,324,650,1/1/2019,2019,2,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",Bial - Portela C S.A.,1,800 mg QD Eslicarbazepine acetate | 1200 mg QD Eslicarbazepine acetate | Placebo,16 years and older,y,nil,>/75,France,2,"North America
South America
Europe
",N
220,NCT00988429,2018,326,324,650,1/1/2019,2019,2,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",Bial - Portela C S.A.,1,800 mg QD Eslicarbazepine acetate | 1200 mg QD Eslicarbazepine acetate | Placebo,16 years and older,y,nil,>/75,Germany,2,"North America
South America
Europe
",N
220,NCT00988429,2018,326,324,650,1/1/2019,2019,2,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",Bial - Portela C S.A.,1,800 mg QD Eslicarbazepine acetate | 1200 mg QD Eslicarbazepine acetate | Placebo,16 years and older,y,nil,>/75,Greece,2,"North America
South America
Europe
",N
220,NCT00988429,2018,326,324,650,1/1/2019,2019,2,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",Bial - Portela C S.A.,1,800 mg QD Eslicarbazepine acetate | 1200 mg QD Eslicarbazepine acetate | Placebo,16 years and older,y,nil,>/75,Italy,2,"North America
South America
Europe
",N
220,NCT00988429,2018,326,324,650,1/1/2019,2019,2,Phase 3,0,n,y,,R,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial",Bial - Portela C S.A.,1,800 mg QD Eslicarbazepine acetate | 1200 mg QD Eslicarbazepine acetate | Placebo,16 years and older,y,nil,>/75,Poland,2,"North America
South America
Europe
",N
221,NCT00939705,2011,10,8,18,,,3,Phase 1,0,n,y,,O,"Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Topiramate (2 x 25 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (TopamaxÔÎ, Ortho-McNeil Neurologics, Inc.) in Fed, Healthy, Adult Subjects",Torrent Pharmaceuticals Limited,1,topiramate,18-55,n,55,55-<65,United States of America,1,North America,n
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Australia,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Croatia,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,czechiaia,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Estonia,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Finland,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Germany,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Hungary,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Lithuania,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Poland,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Romania,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Russian Federation,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Serbia,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,Ukraine,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,,3,"Oceania
Europe",N
222,NCT00693017,2015,2,2,4,,,3,Phase 3,0,n,y,,R,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",Eisai Inc.,1,Zonisamide | Placebo,12_65,y,65,65-<75,,3,"Oceania
Europe",N
223,NCT01432171,2018,24,13,37,,,3,,0,n,y,,R,"Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients With High-Grade Gliomas",M.D. Anderson Cancer Center,2,Lacosamide | Placebo,18 years and older,n,nil,>/75,United States of America,1,North America,N
224,NCT00381537,Banu 2007,61,47,108,,,3,,1,y,n,,R,Prediction of Childhood Epilepsy Outcome in Bangladesh,Institute of Child Health,2,phenobarbitone | carbamazepine,2_16,y,16,</18,Bangladesh,4,Asia,N
225,NCT00004817,Temkin 1999,304,75,379,,,3,Phase 3,1,y,n,,R,Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures,Office of Rare Diseases (ORD),2,phenytoin | valproate sodium,14 years and older,y,nil,>/75,United States of America,1,North America,N
